Methods of Treating Cancer Including CDC7 Inhibitors

JP7579781B2Active Publication Date: 2024-11-08CARNA BIOSCI
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
JP2021516638
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-02-26
Filing Date
2019-08-28
Publication Date
2024-11-08
Estimated Expiration
2039-08-28

AI Technical Summary

Benefits of technology

をもたらす量である。いくつかの態様では、SRA141の有効量は、「治療有効量」である。いくつかの態様では、追加の治療の第2の有効量は、「治療有効量」である。いくつかの態様では、SRA141の有効量および追加の治療の第2の有効量の両方は、「治療有効量」ではない。いくつかの態様では、第2の有効量は、追加の治療に特有であり、すなわち、第2の有効量は、異なる追加の治療について異なる量である。

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007579781000013
    Figure 0007579781000013
  • Figure 0007579781000014
    Figure 0007579781000014
  • Figure 0007579781000015
    Figure 0007579781000015
Patent Text Reader

Abstract

Disclosed herein are therapeutic methods of administering SRA141 as a monotherapy or in combination therapy useful for inhibiting tumor growth, such as in patients with cancer. [Selected Figure] Figure 1A
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of and priority to U.S. Provisional Application No. 62 / 735,778, filed September 24, 2018, U.S. Provisional Application No. 62 / 760,638, filed November 13, 2018, and PCT Application No. PCT / US2019 / 019676, filed February 26, 2019. The contents of each of the above-referenced applications are incorporated by reference in their entirety.

[0002] Sequence Listing N / A [Background technology]

[0003] Cancer is a group of diseases caused by the uncontrolled and unlimited growth of cells in the body. Because cancer cells usually grow faster than normal cells, cancer can be treated by controlling the replication of DNA during cell division, especially chromosome division.

[0004] Cdc7 is a serine-threonine protein kinase enzyme essential for the initiation of DNA replication in the cell cycle. Specifically, Cdc7 forms a complex with cofactors such as Dbf4 (ASK) and phosphorylates its substrate, MCM (minichromosome maintenance) protein. This phosphorylation is said to assemble Cdc45 and DNA polymerase on DNA to form the MCM complex, thereby initiating DNA replication.

[0005] The expression levels of Cdc7 are frequently elevated in various cancer cell lines and human tumor tissues, generating considerable interest in Cdc7 as an anticancer drug target. Cdc7 has been found to be overexpressed not only in commonly established cell lines derived from human tumors, but also in cells harvested from biological tissues.

[0006] Certain Cdc7 inhibitors have been demonstrated to affect the growth of human tumor cells, such as HeLa and HCT116 cells, but show only limited effects on normal cells.

[0007] Currently, there are no effective therapeutic compositions and methods available for the treatment of cancer using Cdc7 inhibitors. Summary of the Invention

[0008] 1. A method of treating cancer, the method comprising: Administering to a subject having cancer a therapeutically effective amount of an SRA141 compound of formula (ID), [ka] Methods are described herein wherein the therapeutically effective amount is an absolute dose of 10-400 mg / day or 10-1000 mg / day.

[0009] In some embodiments, the subject is a human.

[0010] In some embodiments, the therapeutically effective amount is at least 10 mg / day, at least 20 mg / day, at least 40 mg / day, at least 80 mg / day, at least 160 mg / day, or at least 320 mg / day. In some embodiments, the therapeutically effective amount is at least 15 mg / day, at least 25 mg / day, at least 50 mg / day, at least 100 mg / day, at least 150 mg / day, at least 200 mg / day, at least 250 mg / day, at least 300 mg / day, or at least 350 mg / day.

[0011] In some embodiments, the SRA141 compound is administered orally.

[0012] In some embodiments, the SRA141 compound is administered daily. In some embodiments, the SRA141 compound is administered for at least 5 consecutive days, at least 7 consecutive days, or at least 14 consecutive days. In some embodiments, the SRA141 compound is administered according to a dosing schedule selected from the group consisting of 5 days of administration each week followed by 2 days of non-administration, 1 week of daily administration followed by 1, 2, or 3 weeks of non-administration, 2 or 3 weeks of daily administration followed by 1 or 2 weeks of non-administration, and administration on the second and third days of a weekly cycle. In some embodiments, the therapeutically effective amount is administered in a single dose once a day. In some embodiments, half of the therapeutically effective amount is administered twice a day.

[0013] In some embodiments, the cancer is selected from the group consisting of melanoma, uterine cancer, thyroid cancer, blood cancer, bladder cancer, breast cancer, cervical cancer, colorectal cancer (CRC), gastric cancer, endometrial cancer, hepatocellular carcinoma, leukemia, lymphoma, myeloma, non-small cell lung cancer, ovarian cancer, prostate cancer, pancreatic cancer, brain cancer, sarcoma, small cell lung cancer, neuroblastoma, and head and neck cancer. In some embodiments, the cancer is a blood cancer selected from the group consisting of acute myeloid leukemia (AML), chronic myeloid leukemia (CML), chronic eosinophilic leukemia, and diffuse large B-cell lymphoma (DLBCL). In some embodiments, the cancer is AML.

[0014] In some embodiments, the cancer is metastatic colorectal cancer (mCRC). In some embodiments, the mCRC is not classified as having high microsatellite instability (MSI-H) status. In some embodiments, the MSI-H status is determined by detection of repetitive DNA sequences selected from the group consisting of mononucleotide repeat markers, dinucleotide repeat markers, quasi-monomorphic markers, and combinations thereof. In some embodiments, the detection is performed by a method selected from the group consisting of PCR analysis, multiplex PCR analysis, capillary electrophoresis, DNA sequencing, and combinations thereof.

[0015] In some embodiments, the tumor associated with cancer comprises a phenotype selected from the group consisting of chromosomal instability (CIN), axis checkpoint assembly defects, mitotic defects, G1 / S checkpoint defects, and combinations thereof. In some embodiments, the tumor associated with cancer comprises a Wnt signaling pathway mutation. In some embodiments, the Wnt signaling pathway mutation is selected from the group consisting of adenomatous polyposis coli (APC) gene mutation, FAT1 mutation, FAT4 mutation, and combinations thereof.

[0016] In some embodiments, the method further comprises screening the relevant tumor using either an archive or fresh tumor biopsy. In some embodiments, the screening comprises examining the pattern of chromosome segregation by histochemical staining, examining pharmacokinetic markers by histochemical staining, or a combination thereof. In some embodiments, the screening further comprises determining whether the tumor exhibits abnormal mitosis. In some embodiments, the screening is performed before administration of the SRA141 compound. In some embodiments, the screening is performed after administration of the SRA141 compound.

[0017] In some embodiments, the method includes administering a plasma C of greater than 600, greater than 1000, or greater than 1400 ng / mL of an SRA141 compound to a subject after administration. max In some embodiments, the method results in an AUC of the SRA141 compound in the subject after administration of greater than 5800, greater than 11900, or greater than 16400 ng-h / mL. last In some embodiments, the method results in an intratumoral concentration of the SRA141 compound of greater than 500 ng / mL, greater than 600 ng / mL, greater than 900 ng / mL, or greater than 1300 ng / mL in the subject after administration. In some embodiments, the intratumoral concentration is reached after multiple administrations of the SRA141 compound. In some embodiments, the intratumoral concentration is reached after a single dose of the SRA141 compound.

[0018] In some embodiments, the method results in in vivo inhibition of MCM2 phosphorylation. In some embodiments, the in vivo inhibition of MCM2 phosphorylation is at amino acid residue Ser40 or Ser53. In some embodiments, the in vivo inhibition of MCM2 phosphorylation is in a tumor associated with a cancer. In some embodiments, the in vivo inhibition of MCM2 phosphorylation in a tumor associated with a cancer is at least 50% compared to an untreated tumor sample. In some embodiments, the untreated tumor sample is a biopsy obtained before administering the SRA141 compound to the subject. In some embodiments, the in vivo inhibition of MCM2 phosphorylation is after a single dose of the SRA141 compound. In some embodiments, the in vivo inhibition of MCM2 phosphorylation is in the skin of the subject. In some embodiments, the in vivo inhibition of MCM2 phosphorylation is measured by Western blot analysis, immunohistochemistry (IHC), or liquid chromatography mass spectrometry (LC / MS). In some embodiments, the in vivo inhibition of MCM2 phosphorylation is measured in a biopsy of the subject. In some embodiments, in vivo inhibition of MCM2 phosphorylation is measured after multiple administrations of the SRA141 compound. In some embodiments, in vivo inhibition of MCM2 phosphorylation is measured after the SRA141 compound reaches a steady-state plasma concentration.

[0019] In some embodiments, the method results in growth inhibition of a tumor associated with the cancer. In some embodiments, the growth inhibition of the tumor is at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% minimal growth inhibition compared to an untreated tumor. In some embodiments, the growth inhibition of the tumor is at least 47% minimal growth inhibition compared to an untreated tumor. In some embodiments, the growth inhibition of the tumor is at least 93% minimal growth inhibition compared to an untreated tumor. In some embodiments, the method results in regression of a tumor associated with the cancer. In some embodiments, the regression is complete regression. In some embodiments, the method results in cytotoxicity of a tumor associated with the cancer. In some embodiments, the method results in at least a 30% reduction in the sum of the diameters of a tumor associated with the cancer. In some embodiments, the method results in a partial response, complete response, or stable disease in the subject.

[0020] In some embodiments, the method further comprises determining a level of growth inhibition of a tumor or lesion associated with the cancer. In some embodiments, the method comprises comparing a second diameter of the target lesion after administration of SRA141 to a first diameter of the target lesion before administration of SRA141 to determine whether target lesion growth is inhibited. In some cases, the growth of the tumor or lesion is confirmed to be inhibited by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% compared to an untreated tumor or lesion.

[0021] In some embodiments, the method further comprises administering a second therapeutically effective amount of one or more additional therapies to the subject. In some embodiments, the one or more additional therapies comprise an anti-tumor agent. In some embodiments, the anti-tumor agent is selected from the group consisting of a DNA polymerase inhibitor, a receptor tyrosine kinase inhibitor, and a mammalian target of rapamycin (mTOR) pathway inhibitor. In some embodiments, the anti-tumor agent comprises a mitogen-activated protein kinase (MAPK) pathway inhibitor. In some embodiments, the MAPK inhibitor is trametinib. In some embodiments, the anti-tumor agent comprises a retinoid pathway regulator. In some embodiments, the retinoid pathway regulator is bexarotene, an RXR agonist, or tretinoin (all-trans retinoic acid, ATRA), an RAR agonist. In some embodiments, the anti-tumor agent comprises an apoptosis regulator. In some embodiments, the apoptosis regulator comprises an apoptosis inducer. In some embodiments, the apoptosis inducer comprises a BCL-2 inhibitor. In some embodiments, the BCL-2 inhibitor is ABT-199. In some embodiments, the anti-tumor agent comprises a phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway inhibitor. In some embodiments, the PI3K pathway inhibitor is copanlisib. In some embodiments, the anti-tumor agent comprises a PARP inhibitor. In some embodiments, the PARP inhibitor is BMN673. In some embodiments, the anti-tumor agent comprises an Aurora B kinase inhibitor. In some embodiments, the Aurora B kinase inhibitor is barasertib. In some embodiments, the one or more additional therapies are administered daily. In some embodiments, the SRA141 compound and the one or more additional therapies exhibit synergistic effects. [Brief description of the drawings]

[0022] These and other features, aspects, and advantages of the present invention will become better understood with regard to the following description and accompanying drawings.

[0023] [Figure 1A]1 is a graph showing tumor volume in animals treated with SRA141 monotherapy in a mouse xenograft model of acute myeloid leukemia. [Figure 1B] 1 is a graph showing tumor weights in animals treated with SRA141 monotherapy in a mouse xenograft model of acute myeloid leukemia. [Figure 1C] 1 is a graph showing weight change in animals treated with SRA141 monotherapy in a mouse xenograft model of acute myeloid leukemia. [Figure 2A] 1 is a graph showing the mean tumor volume of animals treated with SRA141 monotherapy in a rat xenograft model of acute myeloid leukemia. [Figure 2B] 1 is a graph showing body weight changes in animals treated with SRA141 monotherapy in a rat xenograft model of acute myeloid leukemia. [Figure 2C] 1 is a graph showing tumor volumes for individual subjects treated with SRA141 monotherapy in a rat xenograft model of acute myeloid leukemia. [Figure 3A] 1 is a graph showing the half maximal inhibitory concentration (IC50) of SRA141 in a panel of hematological cancer-derived cell lines. [Figure 3B] A summary of the determined IC50 values ​​categorized by cancer type is shown. [Figure 3C] Illustrates sensitivity to SRA141 between cancer and normal cells. [Figure 3D] Shows the activity of the Cdc7 inhibitors SRA141, TAK-931, and LY-3177833 in multiple cell lines. [Figure 3E] IC50 values ​​are shown using four orthogonal assays designed to measure ATP levels (CTG), metabolic activity (CellTiter-Blue (CTB)), cellular DNA content (CyQuant), and esterase activity (Calcein AM) in seven cell lines after 72 hours (left column) and 144 hours (right column). [Figure 3F] 4 shows IC50 values ​​determined by CTG and CyQuant at 144 hours after different exposure times to SRA141. [Figure 4A] 1 is a graph showing the mean tumor volume of animals treated with SRA141 monotherapy in a patient-derived xenograft (PDX) model of colorectal cancer (CRC). [Figure 4B] 1 is a graph showing body weight change in animals treated with SRA141 monotherapy in a patient-derived xenograft (PDX) model of colorectal cancer (CRC). [Diagram 5] FIG. 1 is a graph showing individual subject tumor volumes for animals treated with SRA141 monotherapy in a patient-derived xenograft (PDX) model of colorectal cancer (CRC). [Figure 6] FIG. 1 is a graph showing the mean tumor volume of animals treated with SRA141 monotherapy at day 32 (D32) of treatment in a patient-derived xenograft (PDX) model of colorectal cancer (CRC). [Figure 7A] 1 is a graph showing the mean tumor volume of animals treated with SRA141 in a rat xenograft model of colon cancer. [Figure 7B] 1 shows percent body weight change, tumor concentration of SRA141, and immunoblot graphs demonstrating reduction of phosphorylated MCM2 12 hours after treatment with SRA141 in a rat xenograft model of colon cancer. [Figure 8] 1 is a graph showing inhibition of cell growth (cell viability compared to untreated controls at 0 and 72 hours) of cell lines continuously treated (pretreated) with SRA141 in combination with an antitumor agent. [Figure 9] 1 shows a table showing synergy scores for growth inhibition of cell lines co-treated with SRA141 ("Sierra Compound 1") in combination with anti-tumor agents. [Figure 10A] 1 shows a table showing synergy scores for growth inhibition of cell lines co-treated with SRA141 ("Sierra Compound 1") in combination with anti-tumor agents. [Figure 10B] 1 is a graph showing the percent growth inhibition of HT-29 cells treated with gemcitabine alone or in combination with SRA141. [Figure 11A] 1 shows potent inhibition of Cdc7 by SRA141 in an in vitro biochemical assay. [Figure 11B] 4 shows the residence time of SRA141 binding to Cdc7 and dissociation kinetics. [Figure 12] The results of kinome screening assays of SRA141 and TAK931 are shown. [Figure 13] Colo-205 cells treated with SRA141 at concentrations of 0.033 and 3.3 μM for 8 h (Figure 13A) to 24 h (Figure 13B), and at concentrations of 0.1 and 1 μM for 3, 6, and 24 h (Figure 13C), as well as MV411 cells treated with SRA141 at concentrations of 0.5 and 3.3 μM with subsequent assessment of the phosphorylation status of downstream targets of Cdc7 (Figure 13D). [Figure 14] 1 is a graph showing quantification of phosphorylation of MCM2 on Ser53 following treatment with SRA141 at 0.1 μM and 1 μM for 24 hours. [Figure 15] Shown are flow cytometry data from cells treated with SRA141 during S phase (Figure 15A) and at the onset of M phase (Figure 15B), assessment of cell cycle and DNA markers in cells treated with SRA141 (Figure 15C), and assessment of the percentage of mitotic cells in cell populations treated with Cdc7 inhibitors (Figure 15D). [Figure 16] A summary of SRA141 sensitivity in cell lines with and without APC mutations is shown. [Figure 17] FIG. 1 is a graph showing the mean tumor volume of animals treated with SRA141 monotherapy in BALB / c mice bearing Colo-205 tumor xenografts. [Figure 18] 1 is a graph showing the mean tumor volume of animals treated with SRA141 monotherapy in BALB / c mice bearing SW620 tumor xenografts. [Figure 19] FIG. 1 is a graph showing the mean tumor volume of animals treated with SRA141 monotherapy in BALB / c mice bearing A20 tumor xenografts. [Figure 20] 1 is a graph showing the mean tumor volume of animals treated with SRA141 monotherapy in CB-17 SCID mice bearing MDA-MB-486 breast tumor xenografts. [Figure 21] 2A-B show decreased pMCM2 levels following a single SRA141 administration in BALB / c mice bearing subcutaneous SW620 tumors (pMCM2 levels shown in FIG. 21A, % inhibition quantified and normalized to actin in FIG. 21B). [Figure 22] 1 shows pMCM2 levels following SRA141 treatment in female Rowett nude rats bearing subcutaneous Colo-205 tumors. [Figure 23] FIG. 1 shows SRA141 plasma concentrations determined by LC-MS / MS in non-tumor bearing female nude rats. [Figure 24A] 1 shows immunohistochemical assessment of total MCM2, phosphorylated MCM2, and gH2AX in tumor and surrogate tissues from a rat xenograft model of leukemia treated with and without SRA141. [Figure 24B] 1 shows immunohistochemical assessment of phosphorylated MCM2 in tumor and surrogate tissues from a rat xenograft model of leukemia. [Figure 24C] 1 shows immunohistochemistry and H&E evaluation of tumors from a rat xenograft model of leukemia treated with SRA141 and vehicle. [Figure 25A] 1 shows the results of evaluation of pMCM2-S40 expression in xenograft tumors following treatment with SRA141 at various doses. [Figure 25B] 1 shows the results of evaluation of pMCM2-S40 expression in skin samples derived from rat xenografts following treatment with SRA141 at various doses. [Figure 26] 1 shows the results of evaluation of total MCM2, pMCM2-S53, pMCM2-S40, and gH2AX in normal human skin. [Figure 27] The results of cell viability assays performed with SRA141 in combination with various additional antitumor agents in Colo-205 cells (Figure 27A, Figure 27G), SW620 cells (Figure 27B), A375 cells (Figure 27C), KG-1 cells (Figure 27D), MOLM-13 cells (Figure 27E, Figure 27H), and MV411 cells (Figure 27F) are shown. [Figure 28] The results of treatment with SRA141 in cells following inhibition of anti-apoptotic genes by RNAi knockdown (FIG. 28A) or treatment with ABT-199 (FIG. 28B) are shown. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0024] Disclosed herein is a method of inhibiting tumor growth in a subject, such as a human, by administering an effective amount of the Cdc7 inhibitor SRA141. Disclosed herein is also a method of inhibiting tumor growth in a subject, such as a human, by administering an effective amount of the Cdc7 inhibitor SRA141. Disclosed herein is also a method of inhibiting tumor growth in a subject, such as a human, by administering an effective amount of the Cdc7 inhibitor SRA141 in combination therapy.

[0025] definition Terms used in the claims and specification are defined as set forth below unless otherwise specified.

[0026] The practice of the present invention involves the use of conventional techniques of organic chemistry, molecular biology (including recombinant techniques), microbiology, cell biology, biochemistry, and immunology, which are within the skill of the art.

[0027] In this application, many technical indications will be referred to. All numerical indications, for example, are approximations that may vary (+) or (-) as appropriate, for example, by increments of 0.01, 0.05, 0.1, 0.5, 1.0, 5.0, or 10.0, including their respective ranges. All numerical indications may be understood to be preceded by the term "about". The reagents described herein are exemplary, and equivalents thereof may be known in the art.

[0028] The compounds utilized in the present invention possess asymmetric carbon atoms (optical centers) or double bonds; the racemates, diastereomers, geometric isomers, positional isomers, and individual isomers (e.g., separate enantiomers) are all intended to be embraced within the scope of the present invention. The compounds of the present invention may also contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute such compounds. For example, the compounds may contain, without limitation, tritium ( 3 H), iodine-125( 125 I), or carbon-14 ( 14 C). All isotopic variations of the compounds of the present invention, whether radioactive or not, are intended to be encompassed within the scope of the present invention.

[0029] The term "subject" refers to any mammal, including mammals such as humans, and animals of veterinary and research interest, including, but not limited to, monkeys, cows, horses, dogs, cats, and rodents.

[0030] The term "administering" a drug and / or therapy to a subject or the term "administration" (and grammatical equivalents of this phrase) refers to both direct or indirect administration, which can be administration to a subject by a medical professional, self-administration, and / or indirect administration, which can be the act of prescribing or persuading a subject to prescribe a drug and / or therapy.

[0031] The term "co-administration" refers to two or more compounds administered in a manner that exerts their pharmacological effect during the same period of time. Such co-administration can be accomplished by either simultaneous, contemporaneous, or sequential administration of the two or more compounds.

[0032] The term "treating" a disorder or disease or "treatment" refers to taking measures to alleviate symptoms of a disorder or disease, such as tumor growth or cancer, or otherwise obtain some beneficial or desired result for a subject, including clinical results. Any beneficial or desired clinical result may include, but is not limited to, alleviation or amelioration of one or more symptoms of cancer or conditional survival and reduction in tumor cell mass or tumor volume, reduction in the extent of disease, delay or slowing of tumor progression or disease progression, improvement, alleviation, or stabilization of the tumor and / or disease state, or other beneficial results.

[0033] The terms "in situ" or "in vitro" refer to processes that take place in living cells grown separate from living organisms, for example, in tissue culture.

[0034] The term "in vivo" refers to a process that takes place in a living organism.

[0035] The term "Cdc7" refers to the cell division cycle 7 serine / threonine protein kinase encoded by the CDC7 gene.

[0036] The term "reduction" of one or more symptoms (and grammatical equivalents of this phrase) refers to a decrease in the severity or frequency of the symptom(s), or elimination of the symptom(s).

[0037] It must be noted that as used in the specification and the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise.

[0038] Methods of the Invention Disclosed herein are methods of inhibiting tumor growth in a subject, such as a human, by administration of the Cdc7 inhibitor SRA141. Detailed descriptions of the compounds, kits containing the compounds, and methods of their use are found below.

[0039] Administration As disclosed herein, the method of the present invention includes administration of an effective amount of SRA141. The present disclosure provides a method of treatment in which an effective amount of SRA141 is administered to a subject. The term "effective amount" or "therapeutically effective amount" refers to an amount effective to ameliorate a disease symptom, for example, an amount effective to inhibit tumor growth. In some embodiments, the effective amount of SRA141 is less than the maximum tolerated dose (MTD). In some embodiments, the effective amount of SRA141 is less than 1000 mg / day, less than 500 mg / day, or less than 400 mg / day. In some embodiments, the effective amount of SRA141 is less than 300 mg / day, less than 200 mg / day, less than 150 mg / day, less than 100 mg / day, or less than 75 mg / day. In some embodiments, the effective amount of SRA141 is less than 324 mg / day. In some embodiments, the effective amount of SRA141 is 324 mg / day. In some embodiments, the effective amount of SRA141 is at least 10 mg / day. In some embodiments, the effective amount of SRA141 is 10-400 mg / day. In some embodiments, the effective amount of SRA141 is 10-324 mg / day. In some embodiments, the effective amount of SRA141 is 40-400 mg / day. In some embodiments, the effective amount of SRA141 is at least 10 mg / day, at least 20 mg / day, at least 40 mg / day, at least 80 mg / day, at least 160 mg / day, or at least 320 mg / day. In some embodiments, the effective amount of SRA141 is at least 15 mg / day, at least 25 mg / day, at least 50 mg / day, at least 75 mg / day, at least 100 mg / day, at least 150 mg / day, at least 200 mg / day, at least 250 mg / day, at least 300 mg / day, or at least 350 mg / day. In some embodiments, the effective amount of SRA141 is 10 mg / day, 20 mg / day, 40 mg / day, 80 mg / day, 160 mg / day, 320 mg / day, 325 mg / day, 350 mg / day, or 400 mg / day. In some embodiments, the effective amount of SRA141 is 15 mg / day, 25 mg / day, 50 mg / day, 75 mg / day, 100 mg / day, 150 mg / day, 200 mg / day, 250 mg / day, 300 mg / day, or 350 mg / day.

[0040] Monotherapy In one embodiment, an effective amount of a Cdc7 inhibitor is administered as a monotherapy.

[0041] In some embodiments, the effective amount of Cdc7 inhibitor monotherapy is less than the maximum tolerated dose (MTD). In some embodiments, the effective amount of Cdc7 inhibitor monotherapy is less than 1000 mg / day, less than 500 mg / day, or less than 400 mg / day. In some embodiments, the effective amount of Cdc7 inhibitor monotherapy is less than 300 mg / day, less than 200 mg / day, less than 150 mg / day, less than 100 mg / day, or less than 75 mg / day. In some embodiments, the effective amount of Cdc7 inhibitor monotherapy is less than 324 mg / day. In some embodiments, the effective amount of SRA141 monotherapy is 324 mg / day. In some embodiments, the effective amount of Cdc7 inhibitor monotherapy is at least 10 mg / day. In some embodiments, the effective amount of Cdc7 inhibitor monotherapy is 10-400 mg / day. In some embodiments, the effective amount of Cdc7 inhibitor monotherapy is 10-324 mg / day. In some embodiments, the effective amount of Cdc7 inhibitor monotherapy is 40-400 mg / day. In some embodiments, the effective amount of Cdc7 inhibitor monotherapy is at least 10 mg / day, at least 20 mg / day, at least 40 mg / day, at least 80 mg / day, at least 160 mg / day, or at least 320 mg / day. In some embodiments, the effective amount of Cdc7 inhibitor monotherapy is at least 15 mg / day, at least 25 mg / day, at least 50 mg / day, at least 75 mg / day, at least 100 mg / day, at least 150 mg / day, at least 200 mg / day, at least 250 mg / day, at least 300 mg / day, or at least 350 mg / day. In some embodiments, an effective amount of SRA141 monotherapy is 10 mg / day, 20 mg / day, 40 mg / day, 80 mg / day, 160 mg / day, 320 mg / day, 325 mg / day, 350 mg / day, or 400 mg / day. In some embodiments, an effective amount of SRA141 monotherapy is 15 mg / day, 25 mg / day, 50 mg / day, 75 mg / day, 100 mg / day, 150 mg / day, 200 mg / day, 250 mg / day, 300 mg / day, or 350 mg / day.

[0042] Combination therapy As disclosed herein, the methods of the invention also include combination therapy in which an effective amount of SRA141 is administered and a second effective amount of one or more additional therapies is co-administered.

[0043] The additional treatment includes, but is not limited to, administration of chemotherapeutic agents, administration of antibodies or antibody fragments (such as immune checkpoint inhibitors), administration of radiation therapy, and combinations thereof. The additional treatment also includes, but is not limited to, administration of antitumor agents, such as DNA polymerase inhibitors, receptor tyrosine kinase inhibitors, mammalian target of rapamycin (mTOR) pathway inhibitors. The antitumor agent can also include mitogen-activated protein kinase (MAPK) pathway inhibitors, such as trametinib. The antitumor agent can also include retinoid pathway regulators, such as bexarotene, an RXR agonist, and tretinoin, an RAR agonist. The antitumor agent can also include apoptosis regulators, such as apoptosis inducers, including, but not limited to, anti-Bcl-2 agents (e.g., ABT-199). The antitumor agent can also include phosphatidylinositol-4,5-bisphosphate 3 kinase (PI3K) pathway inhibitors, such as copanlisib. The antitumor agent can also include PARP inhibitors, such as BMN673. The antitumor agent may also include an ATM kinase inhibitor, such as KU-60019. The antitumor agent may also include an Aurora B kinase inhibitor, such as barasertib. The antitumor agent may also include a tyrosine threonine kinase (TTK) inhibitor, such as an inhibitor of monopolar spindle 1 kinase (Mps1) (e.g., CFI-402257). The antitumor agent may also include an inhibitor of epidermal growth factor (EGF), such as erlotinib. In some embodiments, the antitumor agent is gemcitabine. In some embodiments, the antitumor agent is not gemcitabine.

[0044] The additional treatments can also include combinations of additional treatments, such as combinations of anti-tumor agents.

[0045] In certain embodiments of the invention, an effective amount of SRA141 is administered to a subject as a combination therapy with a second effective amount of an additional treatment. In some aspects, the second effective amount is an amount of about 0.001 mg / kg to about 15 mg / kg. In some embodiments, the second effective amount of the additional treatment is 0.001, 0.005, 0.010, 0.020, 0.050, 0.1, 0.2, 0.5, 1.0, 2.0, 5.0, 10.0, or 15.0 mg / kg. In some embodiments, the second effective amount of the additional treatment is 10 to 2000 mg / m 2 In some embodiments, the second effective amount of the additional treatment is 50 to 1250 mg / m 2 In some embodiments, the second effective amount of the additional therapy is 50 mg / m 2 / day, 100mg / m 2 / day, 150mg / m 2 / day, 200mg / m 2 / day, 300mg / m 2 / day, 400mg / m 2 / day, 500mg / m 2 / day, 600mg / m 2 / day, 700mg / m 2 / day, 800mg / m 2 / day, 900mg / m 2 / day, 1000mg / m 2 / day, 1100mg / m 2 / day, or 1250 mg / m 2 / day.

[0046] Concurrent administration includes methods in which SRA141 and the additional treatment are administered simultaneously, methods in which SRA141 and the additional treatment are administered continuously, and methods in which either SRA141 and one or both of the additional treatments are administered intermittently or continuously, or any combination of simultaneously, continuously, intermittently, and / or continuously. Those skilled in the art will recognize that intermittent administration is not necessarily the same as continuous administration, since intermittent administration also includes a first administration of an agent and then another administration of the same agent at a later time. Those skilled in the art will also understand that intermittent administration also includes continuous administration in some embodiments, since intermittent administration includes interruption of a first administration of an agent with administration of a different agent before the first agent is administered again. Furthermore, those skilled in the art will also know that continuous administration can be achieved by many routes, including intravenous injection or feeding tubes, etc.

[0047] Moreover, in a more general manner, the term "co-administered" encompasses any and all manners in which the respective administration of a Cdc7 inhibitor and the respective administration of an additional therapy to a subject overlap during any time frame.

[0048] Route of administration In some embodiments, the disclosure provides methods in which SRA141 and / or an additional therapy, or both, or any combination thereof, are administered by a route selected from the group consisting of intravenous, subcutaneous, cutaneous, oral, intramuscular, and intraperitoneal. In some embodiments, the disclosure provides methods in which SRA141 and / or an additional therapy, or both, or any combination thereof, are administered intravenously. In some embodiments, the disclosure provides methods in which SRA141 and / or an additional therapy, or both, or any combination thereof, are administered orally.

[0049] It will be understood by those skilled in the art that the unit dosage forms of the present disclosure may be administered in the same or different physical forms, i.e., orally via capsules or tablets, and / or orally, or by liquid via intravenous infusion, etc. Also, the unit dosage form of each administration may vary depending on the specific administration route. Several different dosage forms may exist for one or both of the Cdc7 inhibitor and the additional treatment. Different medical conditions may warrant different administration routes, so the same components of the combination of the Cdc7 inhibitor and the additional treatment described herein may be exactly the same in composition and physical form, but may need to be given in different ways and perhaps at different times to alleviate the condition. For example, conditions such as persistent nausea, especially with vomiting, may make the use of oral dosage forms difficult, and in such cases, it may be necessary to administer another unit dosage form, perhaps the same as the other dosage form used previously or subsequently, instead or in addition to the inhalation, buccal, sublingual, or suppository route. Since various factors such as chemical stability or pharmacokinetics may be problematic, a specific dosage form may be a requirement for a particular combination of SRA141 and the additional treatment.

[0050] Dosing schedule In one embodiment, the frequency of administration of SRA141 or additional treatment to the subject includes, but is not limited to, Q1d, Q2d, Q3d, Q4d, Q5d, Q6d, Q7d, Q8d, Q9d, Q10d, Q14d, Q21d, Q28d, Q30d, Q90d, Q120d, Q240d, or Q365d. The term "QnD or qnd" refers to drug administration once every "n" days. For example, QD (or qd) refers to administration once every day or once a day, Q2D (or q2d) refers to administration once every 2 days, Q7D refers to administration once every 7 days or once a week, Q5D refers to administration once every 5 days, etc. In one embodiment, SRA141 and additional treatment are administered on different schedules.

[0051] In another embodiment, the frequency of administration of SRA141 or the additional treatment to a subject includes, but is not limited to, administration 5 days each week followed by 2 days off, administration daily for 1 week followed by 1, 2, or 3 weeks off, administration daily for 2 or 3 weeks followed by 1 or 2 weeks off, administration twice daily, or administration on days 2 and 3 of a weekly cycle. In one embodiment, SRA141 and the additional treatment are administered on different schedules.

[0052] In one embodiment, the present disclosure provides a method in which either SRA141 and / or one or both of the additional treatments, or any combination thereof, are administered intermittently.In one embodiment, the present disclosure provides a method comprising administering SRA141 or one or both of the additional treatments, or any combination thereof, to a subject with a delay of at least 10 minutes, 15 minutes, 20 minutes, 30 minutes, 40 minutes, 60 minutes, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 14 hours, 18 hours, 24 hours, 36 hours, 48 ​​hours, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 3 weeks, or 4 weeks between administrations. In such embodiments, the administration with a delay follows a pattern in which one, both, or any combination of SRA141 and / or the additional therapy are administered continuously for a given period of time ranging from about 10 minutes to about 365 days, and then not administered for a given period of time ranging from about 10 minutes to about 30 days. In one embodiment, the disclosure provides a method in which either one or any combination of SRA141 and / or the additional therapy is administered intermittently while the other is given continuously.

[0053] In one aspect, the disclosure provides a method in which a combination of an effective amount of SRA141 is administered sequentially with a second effective amount of an additional treatment.

[0054] In one embodiment, the present disclosure provides a method in which SRA141 and an additional treatment are administered simultaneously. In one embodiment, the present disclosure provides a method in which an effective amount of a combination of SRA141 is administered sequentially with a second effective amount of an additional treatment. In such an embodiment, the combination is also said to be "co-administered", as the term includes any and all methods in which a subject is exposed to both components in the combination. However, such an embodiment is not limited to a combination that is provided in only one formulation or composition. Certain concentrations of SRA141 and an additional treatment may be more advantageous to deliver at certain intervals, and as such, the effective amount of SRA141 and the second effective amount of the additional treatment may vary depending on the formulation administered.

[0055] In some embodiments, the present disclosure provides a method in which SRA141 and an additional treatment are administered simultaneously or sequentially. In some embodiments, the present disclosure provides a method in which an effective amount of SRA141 is administered following a second effective amount of an additional treatment. In some embodiments, the present disclosure provides a method in which an effective amount of SRA141 is administered following a second effective amount of an additional treatment.

[0056] In some embodiments, the present disclosure provides a method in which the combination is administered in one composition. In some embodiments, the present disclosure provides a method in which the combination is administered in two compositions, and an effective amount of SRA141 is administered in a separate composition from the composition of the second effective amount of the additional treatment.

[0057] In some embodiments, the present disclosure provides a method in which an effective amount of SRA141 is administered following a second effective amount of an additional treatment. In some embodiments, the present disclosure provides a method in which an effective amount of SRA141 is administered following a second effective amount of an additional treatment. In some embodiments, SRA141 and the additional treatment are administered, and then both SRA141 and the additional treatment are administered intermittently for at least 24 hours. In some embodiments, SRA141 and the additional treatment are administered on a non-overlapping, every other day schedule. In some embodiments, the additional treatment is administered on day 1, and SRA141 is administered on days 2 and 3 of a weekly schedule.

[0058] In some embodiments, the present disclosure provides a method in which an effective amount of SRA141 is administered 4 hours or more after a second effective amount of additional treatment. In one embodiment, the present disclosure provides a method in which an effective amount of SRA141 is administered 10 minutes or more, 15 minutes or more, 20 minutes or more, 30 minutes or more, 40 minutes or more, 60 minutes or more, 1 hour or more, 2 hours or more, 4 hours or more, 6 hours or more, 8 hours or more, 10 hours or more, 12 hours or more, 24 hours or more, 2 days or more, 4 days or more, 6 days or more, 8 days or more, 10 days or more, 12 days or more, 14 days or more, 21 days or more, 30 days or more after a second effective amount of additional treatment. In one aspect, the disclosure provides a method, wherein a second effective amount of an additional treatment is administered 10 minutes or more, 15 minutes or more, 20 minutes or more, 30 minutes or more, 40 minutes or more, 60 minutes or more, 1 hour or more, 2 hours or more, 4 hours or more, 6 hours or more, 8 hours or more, 10 hours or more, 12 hours or more, 24 hours or more, 2 days or more, 4 days or more, 6 days or more, 8 days or more, 10 days or more, 12 days or more, 14 days or more, 21 days or more, 30 days or more after the effective amount of SRA141.

[0059] Cancer and Tumors A method for the treatment of cancer is disclosed.Accordingly, the present disclosure provides a method for treating cancer in a subject in need thereof (i.e., a subject with cancer or a subject suffering from cancer), comprising administering an effective amount of SRA141 to a subject with cancer, wherein the cancer is melanoma, uterine cancer, thyroid cancer, blood cancer, bladder cancer, breast cancer, cervical cancer, colorectal cancer (CRC), gastric cancer, endometrial cancer, bile duct cancer, hepatocellular carcinoma, leukemia, lymphoma, myeloma, non-small cell lung cancer, ovarian cancer, prostate cancer, pancreatic cancer, brain cancer, sarcoma, small cell lung cancer, neuroblastoma, or head and neck cancer.In some embodiments, the cancer is blood cancer, such as acute myeloid leukemia (AML), chronic myeloid leukemia (CML), chronic eosinophilic leukemia, and diffuse large B-cell lymphoma (DLBCL).In some embodiments, the cancer is AML.

[0060] In some aspects, a cancer may be classified as not having microsatellite instability high (MSI-H) status. The term "microsatellite instability" refers to a tumor characterized by genomic instability in specific repetitive DNA sequences (e.g., short tandem repeats or simple sequence repeats). Methods for detecting microsatellite instability include any method known in the art, including but not limited to those methods described in Wang M.et al., Screening for Microsatellite Instability in Colorectal Cancer and Lynch Syndrome-A Mini Review;NAJ Med Sci.2016;9(1):5-11. In certain embodiments, microsatellite instability is characterized by the detection of mononucleotide repeat markers (e.g., BAT-25, BAT-26, NR-21, NR-24, and MONO-27, also known as Promega MSI multiplex system). In certain embodiments, microsatellite instability is characterized by detection of quasi-monomorphic and dinucleotide repeat markers (e.g., BAT25, BAT26, D2S123, D5S346, and D17S250, aka Bathesda panel). MSI can be classified as MSI-high (MSI-H), MSI-Low (MSI-L), and MS-Stable (MSS), with instability at two or more markers classified as MSI-H, instability at only one classified as MSI-L, and no instability observed at five markers as MSS. It can also be classified as MSI-H if more than 30% of the markers tested show instability, MSI-L if 10-30% of the markers tested show instability, and MSS if less than 10% of the markers tested show instability. MSI status can be tested using 5, 6, 7, 8, 9, 10, or more than 10 markers. In some embodiments, the cancer is classified as MSS. The cancer can also have unknown MSI status, i.e., the tumor is not known to have MSI-H status.

[0061] The term "microsatellite instability" in certain embodiments also refers to tumors that are characterized by having one or more repetitive DNA sequences known in the art to correlate with loss of mismatch repair (MMR), as compared to at least one reference sample.

[0062] In some aspects, the present disclosure provides a method of inhibiting tumor growth, wherein the tumor is melanoma, uterine cancer, thyroid cancer, blood cancer, bladder cancer, breast cancer, cervical cancer, colorectal cancer (CRC), gastric cancer, endometrial cancer, biliary tract cancer, hepatocellular carcinoma, leukemia, lymphoma, myeloma, non-small cell lung cancer, ovarian cancer, prostate cancer, pancreatic cancer, brain cancer, sarcoma, small cell lung cancer, neuroblastoma, or head and neck cancer. The tumor may be derived from a blood cancer, such as acute myeloid leukemia (AML), chronic myeloid leukemia (CML), chronic eosinophilic leukemia, and diffuse large B-cell lymphoma (DLBCL). The tumor may be derived from an AML cancer. The tumor may be derived from a metastatic colorectal cancer (mCRC). The tumor may be derived from a metastatic colorectal cancer (mCRC) that is not classified as having MSI-H status. The tumor may have a Wnt signaling pathway mutation, such as an adenomatous polyposis coli (APC) gene mutation, a FAT1 mutation, a FAT4 mutation, or a combination thereof. The tumor may have an FBXW7 mutation.

[0063] In some embodiments, tumors associated with cancer include phenotypes that are prospectively screened using either archival or fresh tumor biopsies, histochemical staining of tumor sections with hematoxylin and eosin (or similar stains) to examine patterns of chromosome segregation and determine whether the tumor exhibits abnormal mitosis (e.g., lagging chromosomes, anaphase bridges, multipolar spindles), e.g., under a microscope, either manually or by automated methods. In some embodiments, pharmacokinetic markers of abnormal mitosis are determined by histochemical staining using post-treatment tumor biopsies after SRA141 administration. Post-treatment biopsies can be obtained several days after SRA141 administration, e.g., biopsies are obtained on the same day for pMCM2 monitoring (see below).

[0064] subject The present disclosure provides for administering an effective amount of SRA141 to a subject in need thereof. The present disclosure provides for administering an effective amount of SRA141 to a subject in need thereof in combination therapy with an additional treatment. In some embodiments, a tumor from a subject is screened with genetic testing and / sequencing before administration. In some embodiments, a tumor from a subject is screened with genetic testing and / sequencing after administration. In some embodiments, a tumor from a subject is screened both after and before administration. In some embodiments, healthy cells from a subject are screened with genetic testing and / sequencing before administration, after administration, or both. In some embodiments, a tumor from a subject is screened with other biological tests or assays to determine the level of expression of a particular biomarker, such as microsatellite or repetitive DNA. In some embodiments, a tumor from a subject is screened with both genetic testing and / sequencing and other biomarker tests or assays.

[0065] In some aspects, the disclosure provides methods, wherein the subject is a mammal, hi some aspects, the disclosure provides methods, wherein the subject is a primate.

[0066] In some aspects, the disclosure provides a method, wherein the subject is a mouse.

[0067] In some aspects, the disclosure provides methods, wherein the subject is a human.

[0068] In some embodiments, the present disclosure provides a method in a human suffering from a cancer selected from the group consisting of melanoma, uterine cancer, thyroid cancer, blood cancer, bladder cancer, breast cancer, cervical cancer, colorectal cancer (CRC), gastric cancer, endometrial cancer, biliary tract cancer, hepatocellular carcinoma, leukemia, lymphoma, myeloma, non-small cell lung cancer, ovarian cancer, prostate cancer, pancreatic cancer, brain cancer, sarcoma, small cell lung cancer, neuroblastoma, or head and neck cancer. In some embodiments, the cancer is a blood cancer, such as acute myeloid leukemia (AML), chronic myeloid leukemia (CML), chronic eosinophilic leukemia, and diffuse large B-cell lymphoma (DLBCL). In some embodiments, the cancer is AML. In some embodiments, the cancer is metastatic colorectal cancer (mCRC). mCRC can be classified as not having MSI-H status.

[0069] In some embodiments, the subject has a tumor with genomic alterations predicted to confer sensitivity to Cdc7 inhibition, such as not having MSI-H status, having a chromosomal instability (CIN) phenotype (e.g., CRC CIN phenotypes are generally mutually exclusive from microsatellite instability (MSI) CRC tumors), having a main axis checkpoint assembly defect, a mitotic defect, a G1 / S checkpoint defect, a Wnt signaling pathway mutation (e.g., an adenomatous polyposis coli (APC) gene mutation, a FAT1 mutation, a FAT4 mutation, or a combination thereof), or a combination thereof.

[0070] Pharmacokinetics The methods described herein for the treatment of cancer include administering to the patient a plasma C of greater than 400 ng / mL, greater than 600 ng / mL, greater than 1000 ng / mL, or greater than 1400 ng / mL of an SRA141 compound. maxThe methods described herein for treating cancer can result in a plasma C of at least 500 ng / mL, at least 600 ng / mL, at least 700 ng / mL, at least 800 ng / mL, at least 900 ng / mL, at least 1000 ng / mL, at least 1100 ng / mL, at least 1100 ng / mL, at least 1200 ng / mL, at least 1300 ng / mL, at least 1400 ng / mL, or at least 1500 ng / mL of the SRA141 compound. max can result.

[0071] The methods described herein for treating cancer include those that provide an AUC of the SRA141 compound of greater than 3000 ng.h / mL, greater than 5800 ng.h / mL, greater than 11900 ng.h / mL, or greater than 16400 ng.h / mL. last The methods described herein for treating cancer can result in an AUC of the SRA141 compound of at least 5000 ng.h / mL, at least 6000 ng.h / mL, at least 7000 ng.h / mL, at least 8000 ng.h / mL, at least 9000 ng.h / mL, at least 10000 ng.h / mL, at least 11000 ng.h / mL, at least 12000 ng.h / mL, at least 13000 ng.h / mL, at least 14000 ngh / mL, at least 15000 ngh / mL, or at least 16000 ngh / mL. last can result.

[0072] The methods described herein for treating cancer can result in intratumoral concentrations of SRA141 compounds of greater than 500ng / mL, greater than 600ng / mL, greater than 900ng / mL, or greater than 1300ng / mL. The methods described herein for treating cancer can result in intratumoral concentrations of SRA141 compounds of at least 500ng / mL, at least 600ng / mL, at least 700ng / mL, at least 800ng / mL, at least 900ng / mL, at least 1000ng / mL, at least 1100ng / mL, at least 1100ng / mL, at least 1200ng / mL, at least 1300ng / mL, at least 1400ng / mL, or at least 1500ng / mL.

[0073] Kinase Inhibition In some embodiments, the methods described herein result in in vivo kinase inhibition, for example, inhibition of MCM2 phosphorylation. As known in the art, multiple origins of replication are established throughout the genome prior to entering S phase and subsequent DNA replication. These replication origins are composed of multiple components, including six minichromosome maintenance proteins (MCM2-7), collectively referred to as pre-replicative replication complexes (pre-RCs). Once pre-RCs are established, Cdc7 phosphorylates MCM2, which initiates S phase entry and DNA replication. As S phase progresses, Cdc7 phosphorylates MCM2 at additional replication origins until DNA replication is complete prior to entering the next phase of the cell cycle. Thus, MCM2 phosphorylation can be used as a surrogate marker for Cdc7 activity.

[0074] Disclosed herein is a method of treating cancer that results in in vivo inhibition of MCM2 phosphorylation, such as phosphorylation at amino acid residues Ser40 or Ser53. The in vivo inhibition of MCM2 phosphorylation can be a tumor associated with the cancer. The in vivo inhibition of MCM2 phosphorylation in a tumor can be at least 50% compared to an untreated tumor sample. The in vivo inhibition of MCM2 phosphorylation in a tumor can be at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% compared to an untreated tumor sample. The in vivo inhibition of MCM2 phosphorylation can be in the skin of a subject. The in vivo inhibition of MCM2 phosphorylation can be measured by assays known to those skilled in the art, including, but not limited to, Western blot analysis, immunohistochemistry (IHC), liquid chromatography-mass spectrometry (LC / MS), or LC / MS / MS. The in vivo inhibition of MCM2 phosphorylation can be measured in a biopsy of a subject.

[0075] The methods described herein for treating cancer may not result in (i.e., may avoid) specific inhibition of off-target kinases in a subject, and the off-target kinases are selected from the group consisting of WEE1, CDK7, CDK8, CDK9, and LATS2. The methods described herein for treating cancer may result in less than 90% inhibition of off-target kinases.

[0076] Tumor Inhibition The present disclosure is directed to a method of inhibiting tumor progression, reducing the size of the aggregates of the aggregates, reducing their volume, reducing their diameter, and / or otherwise inhibiting their growth using an effective amount of a compound, e.g., SRA141. Thus, the methods described herein for treating cancer can result in growth inhibition of tumors associated with cancer. The methods described herein for treating cancer can result in cytotoxicity of tumors associated with cancer. The methods described herein for treating cancer can result in growth inhibition and cytotoxicity of tumors associated with cancer. The methods described herein for treating cancer can result in growth inhibition or cytotoxicity of tumors associated with cancer. The methods described herein for treating cancer can result in regression of tumors associated with cancer, including complete regression or partial regression. Also provided herein is a method of treating an underlying disease, e.g., cancer, and prolonging the survival of a subject.

[0077] In one embodiment, a method of inhibiting tumor growth in a subject in need thereof is provided, comprising administering to the subject an effective amount of SRA141. In some aspects, the disclosure provides a method of administering to a subject an effective amount of SRA141 to inhibit tumor growth, whereby tumor growth is reduced by at least 47%. In some aspects, the disclosure provides a method of administering to a subject an effective amount of SRA141 to inhibit tumor growth, whereby tumor growth is reduced by at least 93%. In some aspects, the disclosure provides a method of administering to a subject an effective amount of SRA141 to inhibit tumor growth, whereby tumor growth is reduced by at least 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 12%, 14%, 16%, 18%, 20%, 22%, 24%, 26%, 28%, 30%, 32%, 36%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, 102%, 104%, 106%, 108%, 10 The present invention provides a method for reducing the amount of oxidative stress that can be achieved by: 4%, 36%, 38%, 40%, 42%, 44%, 46%, 48%, 50%, 52%, 54%, 56%, 58%, 60%, 62%, 64%, 66%, 68%, 70%, 72%, 74%, 76%, 78%, 80%, 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, 98%, or 100% reduction. In some embodiments, the disclosure provides a method of administering to a subject an effective amount of SRA141 to inhibit tumor growth, where the tumor growth is at least 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 12%, 14%, 16%, 18%, 20%, 22%, 24%, 26%, 28%, 30%, 32%, 36%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, 102%, 104%, 106%, 108%, 109%, 110%, 111%, 112%, 113%, 114%, 115%, 116%, 117%, 118%, 120%, 122%, 124%, 126%, 128%, 129%, 130%, 132%, 133%, 134%, 135%, 136%, 137%, 138%, 140%, 1 %, 34%, 36%, 38%, 40%, 42%, 44%, 46%, 48%, 50%, 52%, 54%, 56%, 58%, 60%, 62%, 64%, 66%, 68%, 70%, 72%, 74%, 76%, 78%, 80%, 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, 98%, or 100% reduction.In some embodiments, the disclosure provides a method of administering an effective amount of SRA141 to a subject to inhibit tumor growth, where the tumor growth is at least 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 12%, 14%, 16%, 18%, 20%, 22%, 24%, 26%, 28%, 30%, 32%, 34%, 36%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, 102%, 104%, 106%, 108%, 109%, 110%, 111%, 112%, 113%, 114%, 115%, 116%, 117%, 118%, 120%, 122%, 124%, 126%, 128%, 129%, 130%, 131%, 132%, 133%, 134%, 135%, 136%, 137%, 13 8%, 30%, 32%, 34%, 36%, 38%, 40%, 42%, 44%, 46%, 48%, 50%, 52%, 54%, 56%, 58%, 60%, 62%, 64%, 66%, 68%, 70%, 72%, 74%, 76%, 78%, 80%, 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, 98%, or 100% reduction. The present disclosure is also directed to a method of inhibiting tumor progression, reducing the size of the tumor aggregates, reducing the volume, reducing the diameter, and / or otherwise inhibiting the growth of the tumor using an effective amount of compound SRA141 and a second effective amount of an additional treatment. Also provided herein is a method of treating an underlying disease, e.g., cancer, and prolonging the survival of a subject.

[0078] In one embodiment, a method of inhibiting tumor growth in a subject in need thereof, the method comprising administering to the subject an effective amount of SRA141 and a second effective amount of an additional treatment. In some aspects, the disclosure provides a method of administering to a subject an effective amount of SRA141 and a second effective amount of an additional treatment to inhibit tumor growth, the method comprising administering to the ... 8%, 30%, 32%, 34%, 36%, 38%, 40%, 42%, 44%, 46%, 48%, 50%, 52%, 54%, 56%, 58%, 60%, 62%, 64%, 66%, 68%, 70%, 72%, 74%, 76%, 78%, 80%, 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, 98%, or 100% decrease. In some embodiments, the disclosure provides a method of administering to a subject an effective amount of SRA141 and a second effective amount of an additional therapy to inhibit tumor growth, where the tumor growth is at least 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 12%, 14%, 16%, 18%, 20%, 22%, 24%, 26%, or more percentiles as measured by absolute tumor size. , 28%, 30%, 32%, 34%, 36%, 38%, 40%, 42%, 44%, 46%, 48%, 50%, 52%, 54%, 56%, 58%, 60%, 62%, 64%, 66%, 68%, 70%, 72%, 74%, 76%, 78%, 80%, 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, 98%, or 100% decrease.In some embodiments, the disclosure provides a method of administering to a subject an effective amount of SRA141 to inhibit tumor growth and a second effective amount of an additional therapy, where the tumor growth is at least 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 12%, 14%, 16%, 18%, 20%, 22%, 24%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, 102%, 104%, 106%, 108%, 109%, 109%. 4%, 26%, 28%, 30%, 32%, 34%, 36%, 38%, 40%, 42%, 44%, 46%, 48%, 50%, 52%, 54%, 56%, 58%, 60%, 62%, 64%, 66%, 68%, 70%, 72%, 74%, 76%, 78%, 80%, 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, 98%, or 100% decrease.

[0079] Clinical endpoints A method for treating cancer, for example, for inhibiting tumor growth and / or inhibiting tumor cell growth in a subject, wherein the method results in a clinically relevant endpoint.

[0080] Tumor growth occurs when one or more biological cells grow and divide much more rapidly, resulting in an increase in cell number compared to the normal and healthy process of cell division. This phenomenon is a sign that the cells are in a disease state, such as cancer or pre-cancer. Also, tumor growth often occurs in a separate stage before the aggregated cells form a tumor.

[0081] There are several methods that a person skilled in the art can use to measure cell replication rates. The overall metabolic activity in the cell can be measured through labeled biological products. For example, there are several commercially available dyes (e.g., MTT) that can permeate cells and interact with certain enzymes and other factors to generate detectable products. Cell biomarkers can also be measured in cells. For example, the BrdU assay incorporates thymidine derivatives into cellular DNA and can be detected with antibodies. Proliferating cell nuclear antigen (PCNA) is another such biomarker for detection. Besides tagging techniques, a person skilled in the art can also use, for example, microscopy or flow cytometry to allow cell counting.

[0082] In one embodiment, cell replication is measured by clinical endpoints including quality of life (QOL) score, duration of response (DOR, clinical benefit rate (CBR), patient reported outcomes (PRO), objective response rate (ORR) score, disease free survival (DFS) or progression free survival (PFS), time to progression (TTP), overall survival, time to treatment failure (TTF), RECIST criteria, partial response (PR), stable disease (SD), progressive disease (PD), and / or complete response (CR). Clinical endpoints can be determined using methods well known to those of skill in the art.

[0083] In some embodiments, CR is the disappearance of all target lesions, with any pathological lymph nodes (either target or non-target) reduced to a short axis of <10 mm. In some embodiments, PR is at least a 30% reduction in the sum of the diameters of target lesions, with reference to the baseline sum diameter. In some embodiments, PD is at least a 20% increase in the diameters of target lesions, with reference to the minimum sum (including the baseline sum, if it is the minimum). In some embodiments, the sum can show an absolute increase of at least 5 mm in addition to a relative increase of 20%. In some embodiments, with reference to the minimum sum diameter, SD is neither shrinking enough to qualify for PR nor increasing enough to qualify for PD.

[0084] In some aspects, the disclosure provides methods in which tumor growth is reduced by at least about 5, 10, 20, 30, 40, 50, 60, 80, 90, 95, 97, 99, or 99.9% following administration of an effective amount of SRA141.

[0085] In some aspects, the disclosure provides methods in which the % reduction is calculated based on the measurement(s) of one or more clinical endpoints.

[0086] In some aspects, the disclosure provides methods in which tumor growth is reduced by at least 5, 10, 20, 30, 40, 50, 60, 80, 90, 95, 97, 99, or 99.9%, or less, following administration of an effective amount of SRA141, as measured by an increase or decrease in total cell count in an MTT assay or by a change in genetic profile measured by a ctDNA assay.

[0087] In some general aspects, the disclosure provides methods in which tumor growth is reduced by at least 5, 10, 20, 30, 40, 50, 60, 80, 90, 95, 97, 99, or 99.9% after administration of an effective amount of SRA141. In some aspects, the disclosure provides methods in which tumor growth is reduced by at least 5, 10, 20, 30, 40, 50, 60, 80, 90, 95, 97, 99, or 99.9% after administration of an effective amount of SRA141, as measured by an increase or decrease in total cell count in an MTT assay or by a change in genetic profile measured by a ctDNA assay.

[0088] In some embodiments, the present disclosure provides an IC 50 value and / or GI less than 1 μM 50 In some embodiments, the disclosure provides a method for producing an IC value of less than 10 μM at 24 hours after administration. 50 value and / or GI less than 1 μM 50 In some embodiments, the disclosure provides a method for producing an IC value of less than 10 μM at 48 hours after administration. 50 value and / or GI less than 1 μM50 Provide a method for producing value.

[0089] In some embodiments, the disclosure provides methods wherein administration results in an AUC of at least 1, 10, 25, 50, 100, 200, 400, 600, 800, or 1000.

[0090] In some embodiments, administration provides an IC of 0.001, 0.005, 0.01, 0.05, 0.1, 1, 3, 5, 10, 20, 40, 50, 60, 80, 90, 100, 200, 250, 300, 350, or 400 μM or less. 50 Provide a method for producing value.

[0091] In some embodiments, the disclosure provides that administration provides an EC of at least 0.01, 0.1, 1, 3, 5, 10, 20, 40, 50, 60, 80, 90, 100, 200, 250, 300, 350, or 400 μM. 50 Provide a method for producing value.

[0092] In some embodiments, the disclosure provides methods where administration results in a therapeutic index (TI) value in the range of about 1.001:1 to about 50:1, about 1.1:1 to about 15:1, about 1.2:1 to about 12:1, about 1.2:1 to about 10:1, about 1.2:1 to about 5:1, or about 1.2:1 to about 3:1.

[0093] In some embodiments, the present disclosure provides a method for treating atherosclerosis, comprising administering a GI of at least 0.1 μM, 0.3 μM, 0.5 μM, 0.7 μM, 1 μM, 1.5 μM, 2 μM, 2.5 μM, 3 μM, 4 μM, 5 μM, or 10 μM. 50 Provide a method for producing value.

[0094] In some aspects, the disclosure provides methods where administration results in a maximum observed response (maximal response) value of 0.1, 0.5, 1, 2 μM, 2.5 μM, 3 μM, 4 μM, 5 μM, or 10 μM or less.

[0095] Tumor growth can be expressed in terms of total tumor volume.There are both general and specific formulas for specific tumor models that can be used by those skilled in the art to calculate tumor volume based on the assumption that solid tumors are roughly spherical.In this regard, those skilled in the art can use ultrasound imaging, manual or digital calipers, ultrasound examination, computed tomography (CT), micro-CT, etc. to measure tumor volume. 18Experimental tools such as F-FDG-microPET, or magnetic resonance imaging (MRI) can be used. For example, Monga SP, Wadleigh R, Sharma A, et al.Intratumoral therapy of cisplatin / epinephrine injectable gel for palliation in patients with obstructive esophageal cancer.Am.J.Clin.Oncol.2000;23(4):386-n392;Mary M.Tomayko C.,Patrick Reynolds,1989.Determination of subcutaneous tumor size in athymic(nude)mice.Cancer Chemotherapy and Pharmacology,Volume 24,Issue 3,pp 148-154;E Richtig,G Langmann,K Mullner,G Richtig and J Smolle,2004.Calculated tumour volume as a prognostic parameter for survival in choroidal melanomas.Eye(2004)18,619-623;Jensen et al.BMC Medical Imaging 2008.8:16; Tomayko et al. Cancer Chemotherapy and Pharmacology September 1989, Volume 24, Issue 3, pp 148-154, and Faustino-Rocha et al. Lab Anim (NY). 2013 June;42(6):217-24, each of which is incorporated by reference herein in its entirety.

[0096] In some embodiments, the disclosure provides methods where administration results in at least a 5, 10, 20, 30, 40, 50, 60, 80, 90, 95, 97, 99, or 99.9% reduction in tumor volume after administration of an effective amount of SRA141. In some embodiments, the disclosure provides methods where administration results in at least a 5, 10, 20, 30, 40, 50, 60, 80, 90, 95, 97, 99, or 99.9% reduction in tumor size after administration of an effective amount of SRA141.

[0097] In some aspects, the disclosure provides methods wherein administration results in at least a 5% reduction in tumor volume after 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, or 52 weeks.

[0098] To assess objective response or tumor growth, the overall tumor burden at baseline may be estimated and used as a comparator for subsequent measurements. Measurable disease may be defined by the presence of at least one measurable lesion.

[0099] In some embodiments, the present disclosure provides a method in which, if multiple measurable lesions are present at baseline, all lesions, up to a total of up to five lesions (and up to two lesions per organ) representative of all involved organs, are identified as target lesions and recorded and measured at baseline. In some embodiments, the target lesions are selected based on their size (lesions with the longest diameter) and are representative of all involved organs. In some embodiments, the target lesions are suitable for reproducible repeated measurements. In some cases, as exemplified in Eisenhauer, et.al. (2009) in Figure 3, in a situation where the next largest lesion that can be reproducibly measured is selected, the largest lesion is not suitable for reproducible measurement.

[0100] A pathological lymph node is defined as measurable if the node has a short axis of 15 mm or greater by CT scan, and in some cases may be identified as a target lesion. In some embodiments, the short axis of the node contributes to the baseline sum. In some embodiments, the short axis of the node is the diameter used by radiologists to determine if the node is involved by a solid tumor. In some embodiments, the node size is reported as two dimensions in the plane in which the image is acquired (e.g., axial plane for CT scans, axial, sagittal, or coronal plane for MRI scans, depending on the plane of acquisition of the scan). In some embodiments, the smaller of the dimensions is the short axis. In some embodiments, a pathological node with a short axis of 10 mm or greater but <15 mm is considered a non-target lesion. In some embodiments, a node with a short axis of <10 mm is considered non-pathological and is not recorded or tracked.

[0101] In some embodiments, the sum of the diameters (longest for non-nodal lesions, short axis for nodal lesions) for all target lesions is calculated and reported as baseline sum diameter. In some embodiments, when lymph nodes are included in the sum, only the short axis is added to the sum. In some embodiments, baseline sum diameter is used as a reference to characterize objective tumor growth or regression.

[0102] In some embodiments, all other lesions or sites of disease (including pathological lymph nodes) are identified as non-target lesions and recorded at baseline. In some cases, no measurements are required and lesions are tracked as "present," "absent," or "definite progression." In some cases, multiple non-target lesions involving the same organ (e.g., "multiple pelvic lymph node enlargement" or "multiple liver metastases") may be recorded.

[0103] Therapeutically Effective Amounts and Unit Dosage Forms Generally, the compound of the present technology will be administered in a therapeutically effective amount by any of the accepted administration modes of drugs that provide similar utility.The actual amount of the compound of the present technology, i.e., active ingredient, will depend on many factors, such as the severity of the disease to be treated, the age and relative health of the subject, the potency of the compound used, the route and form of administration, and other factors well known to those skilled in the art.The drug can be administered at least once a day, preferably once or twice a day.

[0104] The effective amount of such drugs, as well as the most effective and convenient route of administration and the most suitable formulation, can be easily determined by routine experimentation.Various formulations and drug delivery systems are available in the art.See, for example, Gennaro, AR, ed..(1995) Remington's Pharmaceutical Sciences, 18th ed., Mack Publishing Co.

[0105] The therapeutically effective dose can be estimated initially using various techniques well known in the art. The initial dose used in animal experiments can be based on the effective concentration established in cell culture assays. The dosage range suitable for human subjects can be determined, for example, using the data obtained from animal experiments and cell culture assays.

[0106] An effective or therapeutically effective amount or dose of an agent, e.g., a compound used in the methods described herein, e.g., the Cdc7 inhibitor SRA141, refers to the amount of the agent or compound that results in amelioration of symptoms or prolongation of survival in a subject. Toxicity and therapeutic efficacy of such molecules can be determined by standard pharmaceutical procedures in cell culture or experimental animals, e.g., LD 50 (a dose lethal to 50% of the population) and ED 50The therapeutic index can be determined by determining the therapeutic dose (the dose that is therapeutically effective in 50% of the population), as well as the minimal effective concentration (MEC) or minimal effective dose (MED). The dose ratio of toxic to therapeutic effect is the therapeutic index, which can be expressed as the ratio of the MTD or highest non-serious toxic dose (HNSTD) to the MED. Agents that exhibit a high therapeutic index are preferred.

[0107] An effective amount or therapeutically effective amount is that amount of a compound or pharmaceutical composition that will elicit the biological or medical response in a tissue, system, animal, or human that is being sought by a researcher, veterinarian, physician, or other clinician. The dosage may be administered at any dose that is sufficient to cause little or no toxicity. 50 The dosage may vary within this range depending on the dosage form employed and / or the route of administration utilized. The exact formulation, route of administration, dosage, and administration interval should be selected according to methods known in the art, taking into account the specifics of the subject's condition.

[0108] Dosage and interval may be adjusted individually to provide a plasma level of the active moiety sufficient to achieve the desired effect, i.e., the minimum effective concentration (MEC). The MEC varies for each compound, but can be estimated, for example, from in vitro data and animal experiments. The dosage required to achieve the MEC will depend on individual characteristics and route of administration. In the case of local administration or selective uptake, the effective local concentration of the drug may not be related to the plasma concentration.

[0109] The amount of agent or composition administered will depend on a variety of factors, including the sex, age, and weight of the subject being treated, the severity of the affliction, the manner of administration, and the judgment of the prescribing physician.

[0110] The therapeutically effective amount can be the same as or different from either or both of the effective amount of SRA141 and the second effective amount of the additional therapy. This is because the present disclosure provides that the methods described herein are effective even if neither the effective amount of SRA141 nor the second effective amount of the additional therapy alone is an amount that improves the symptoms of the disease (e.g., the amount of SRA141 and / or the additional therapy may be considered a "sub-therapeutic" amount when administered as individual therapies). However, the present disclosure provides that a therapeutically effective amount of the combination must be provided, i.e., the combination affects at least the treatment of the symptoms of the disease.

[0111] Unit dose form is a term commonly understood by those skilled in the art. Unit dose form is a pharmaceutical preparation sold for a specific use. The preparation contains active ingredient(s) and inactive ingredients, most often in the form of a pharmaceutically acceptable carrier or excipient. It is understood that multiple unit dose forms are different preparations. Thus, one unit dose form may be, for example, 250mg of SRA141 in a combination with an additional treatment in a specific ratio of each component, and another completely different unit dose form may be, for example, 750mg of SRA141 in the same specific ratio of each component above in a combination with an additional treatment. Thus, depending on the unit dose form, the effective amount of SRA141 and the second effective amount of the additional treatment may both remain the same. Of course, if either the effective amount of SRA141 or the second effective amount of the additional treatment changes, the unit dose form is different.

[0112] In some embodiments, the effective amount is specific to the SRA141 compound, i.e., different from the second effective amount of the additional treatment. In some embodiments, the effective amount of SRA141 is an amount equal to a "therapeutically effective amount" or an amount that produces a therapeutic effect and / or a beneficial effect. In some embodiments, the effective amount of SRA141 is a "therapeutically effective amount". In some embodiments, the second effective amount of the additional treatment is a "therapeutically effective amount". In some embodiments, both the effective amount of SRA141 and the second effective amount of the additional treatment are not "therapeutically effective amounts". In some embodiments, the second effective amount is specific to the additional treatment, i.e., the second effective amount is a different amount for different additional treatments.

[0113] In some embodiments, the combination of SRA141 and additional therapy is formulated in one unit dosage form. In some embodiments, the same unit dosage form is administered for at least 4 hours, 6 hours, 8 hours, 12 hours, 24 hours, 1 day, 2 days, 3 days, 7 days, 10 days, 14 days, 21 days, or 30 days.

[0114] In some embodiments, the combination of SRA141 and additional treatment is formulated in at least two separate and distinct unit dosage forms. In some embodiments, the first effective amount is different in the first unit dosage form from the second unit dosage form. In some embodiments, the effective amount of SRA141 is the same in the first unit dosage form as in the second unit dosage form.

[0115] In some embodiments, the first unit dosage form is the same as the second unit dosage form. In some embodiments, the first unit dosage form is the same as the second and third unit dosage forms. In some embodiments, the first unit dosage form is the same as the second, third, and fourth unit dosage forms.

[0116] Compounds of the Invention In one aspect, the disclosure provides methods of using the compound SRA141.

[0117] SRA141 The compound SRA141 is also identified by the chemical name: ethyl 5-(1H-pyrrolo[2,3-b]pyridin-3-yl)methylene 4-oxo-2-{[4-(2,2,2-trifluoroethyl)piperazinyl]amino-4,5-dihydrofuran-3-carboxylate.

[0118] SRA141 is a compound disclosed in International Patent Publication No. WO2012133802, which is incorporated herein by reference for all that it teaches. Those skilled in the art will find in International Patent Publication No. WO2012133802 methods for synthesizing SRA141.

[0119] The SRA141 structure is shown below: [ka]

[0120] Pharmaceutical Compositions Methods for inhibiting tumor growth, inhibiting cancer progression, or treating cancer are described herein. The methods include administering an effective amount of SRA141, and optionally a second effective amount of an additional treatment. SRA141 and the additional treatment can each be formulated into a pharmaceutical composition. These pharmaceutical compositions can contain, in addition to the active compound(s), pharma- ceutical acceptable excipients, carriers, buffers, stabilizers, or other materials known to those skilled in the art. Such materials should be non-toxic and should not interfere with the effectiveness of the active ingredient. The exact nature of the carrier or other materials can depend on the route of administration, for example, oral, intravenous, cutaneous or subcutaneous, intranasal, intramuscular, intraperitoneal.

[0121] The pharmaceutical composition for oral administration can be in tablet, capsule, powder, or liquid form. Tablets can contain solid carriers such as gelatin. Liquid pharmaceutical compositions generally contain liquid carriers such as water, petroleum derivatives, animal or vegetable oils, mineral oil, or synthetic oil. Physiological saline, dextrose or other sugar solution, or glycols such as ethylene glycol, propylene glycol, or polyethylene glycol can be included.

[0122] For intravenous, cutaneous or subcutaneous injection, or injection at affected site, active ingredient will be in the form of parenterally acceptable aqueous solution that is pyrogen-free and has appropriate pH, isotonicity and stability.Those skilled in the art can fully prepare appropriate solution using isotonic vehicle such as sodium chloride injection, Ringer's injection, lactate Ringer's injection, etc.Preservatives, stabilizers, buffers, antioxidants and / or other additives can be included as necessary.

[0123] The compositions may be administered alone or in combination with other treatments, either simultaneously or sequentially depending on the condition being treated.

[0124] The present technology is not limited to any particular composition or pharmaceutical carrier, as it may vary.Generally, the compound of the present technology will be administered as a pharmaceutical composition by any one of the following routes: oral, systemic (e.g., transdermal, intranasal, or suppository), or parenteral (e.g., intramuscular, intravenous, or subcutaneous) administration.The preferred method of administration is oral, using a convenient daily dosage regimen that can be adjusted according to the degree of disease.The composition can take the form of a tablet, pill, capsule, semisolid, powder, sustained release formulation, solution, suspension, elixir, aerosol, or other suitable composition.Another preferred method for administering the compound of the present technology is inhalation.

[0125] The choice of formulation depends on various factors such as the mode of drug administration and the bioavailability of the drug substance. For delivery by inhalation, the compound can be formulated as a liquid solution, suspension, aerosol propellant, or dry powder and loaded into a dispenser suitable for administration. There are several types of pharmaceutical inhalation devices, nebulizer inhalers, metered dose inhalers (MDIs), and dry powder inhalers (DPIs). Nebulizer devices generate a high velocity air stream that causes the therapeutic agent (formulated in liquid form) to spray as a mist that is carried to the subject's airways. MDIs are typically formulations packaged with compressed gas. Upon actuation, the device releases a measured amount of the therapeutic agent by compressed gas, thus providing a reliable method of administering a set amount of the drug. DPIs dispense the therapeutic agent in the form of a free-flowing powder that can be dispersed by the device into the subject's inspiratory air stream during breathing. To achieve a free-flowing powder, the therapeutic agent is formulated with an excipient such as lactose. A measured amount of the therapeutic agent is stored in a capsule form and dispensed with each actuation.

[0126] Pharmaceutical dosage forms of the compounds of the present technology can be manufactured by any of the methods well known in the art, such as, for example, conventional mixing, sieving, dissolving, melting, granulating, dragee-making, tabletting, suspending, extrusion, spray-drying, elutriation, emulsifying, (nano / micro)encapsulation, encapsulation, or lyophilization processes. As mentioned above, the compositions of the present technology can contain one or more physiologically acceptable inactive ingredients that facilitate processing of the active molecules into preparations for pharmaceutical use.

[0127] Recently, pharmaceutical formulations have been developed for drugs that exhibit particularly low bioavailability, based on the principle that bioavailability can be increased by increasing the surface area, i.e., by decreasing the particle size. For example, US Patent No. 4,107,288 describes a pharmaceutical formulation having particles in the size range of 10-1,000 nm in which the active material is supported on a crosslinked matrix of polymers. US Patent No. 5,145,684 describes the preparation of a pharmaceutical formulation in which the drug substance is ground into nanoparticles (average particle size of 400 nm) in the presence of a surface modifier, which are then dispersed in a liquid medium resulting in a pharmaceutical formulation that exhibits significantly higher bioavailability.

[0128] The composition generally comprises the compound of the present technology combined with at least one pharma-ceutically acceptable excipient.Acceptable excipient is non-toxic, aids administration, and does not adversely affect the therapeutic benefits of the claimed compound.Such excipient can be any solid, liquid, semi-solid, or in the case of aerosol composition, gaseous excipient that is generally available to those skilled in the art.

[0129] Solid pharmaceutical excipients include starch, cellulose, talc, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, magnesium stearate, sodium stearate, glycerol monostearate, sodium chloride, nonfat dry milk, etc. Liquid and semi-solid excipients can be selected from glycerol, propylene glycol, water, ethanol, and various oils, including those of petroleum, animal, or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil, etc. Particularly for injectable solutions, preferred liquid carriers include water, saline, aqueous dextrose, and glycols.

[0130] Compressed gas can be used to disperse the compound of the present technology in aerosol form. Suitable inert gases for this purpose include nitrogen, carbon dioxide, etc. Other suitable pharmaceutical excipients and their formulations are described in Remington's Pharmaceutical Sciences, edited by EW Martin (Mack Publishing Company, 18th ed., 1990).

[0131] In some embodiments, the pharmaceutical composition comprises a pharmaceutically acceptable salt.The term "pharmaceutically acceptable salt" refers to the salt derived from various organic and inorganic counterions well known in the art, including, by way of example only, sodium, potassium, calcium, magnesium, ammonium and tetraalkylammonium, and, when the molecule contains a basic functional group, the salt of an organic or inorganic acid, such as hydrochloride, hydrobromide, tartrate, mesylate, acetate, maleate and oxalate.Suitable salts include those described in Stahl and Wermuth (Eds.), Handbook of Pharmaceutical Salts Properties, Selection, and Use; 2002.

[0132] The composition can be provided in a pack or dispenser device that contains one or more unit dosage forms containing active ingredient as desired.Such a pack or device can be, for example, metal or plastic foil such as blister pack, or glass, and rubber stopper such as vial.The pack or dispenser device can also be accompanied by instructions for administration.The composition that contains the compound of the present technology formulated in a compatible pharmaceutical carrier can also be prepared, placed in a suitable container, and labeled for the treatment of indicated conditions.

[0133] The amount of the compound in the formulation can vary within the full range used by those skilled in the art. Typically, the formulation contains, on a weight percent (wt%) basis, about 0.01-99.99% by weight of the compound of the present technology based on the total formulation, with the remainder being one or more suitable pharmaceutical excipients. Preferably, the compound is present at a level of about 1-80% by weight. Representative pharmaceutical formulations are described below.

[0134] Example formulation The following are representative pharmaceutical formulations containing SRA141 and additional treatments, either alone or in combination.

[0135] The compositions may be administered alone or in combination with other treatments, either simultaneously or sequentially depending on the condition being treated.

[0136] kit The present disclosure also provides kits comprising a combination of SRA141 and, optionally, an additional treatment, and instructions for use. The present disclosure further provides kits comprising one or more pharmaceutical compositions, the pharmaceutical composition(s) comprising SRA141 and an additional treatment, and instructions for use, optionally, the combination comprising at least one pharma- ceutically acceptable carrier or excipient.

[0137] The individual components of the kit may be packaged in separate containers and associated with such containers may be a notice in a form prescribed by a government agency regulating the manufacture, use, or sale of pharmaceutical or biological products, which notice reflects approval by the agency of the manufacture, use, or sale. The kit may optionally contain instructions or directions outlining the method of use or administration regimen of the antigen-binding construct.

[0138] In some aspects, the disclosure provides kits comprising a combination of SRA141 and an additional therapy and at least one pharma- ceutically acceptable carrier or excipient.

[0139] Where one or more components of the kit are provided as a solution, e.g., an aqueous solution, or a sterile aqueous solution, the container means may itself be an inhaler, syringe, pipette, eye dropper, or other such similar device from which the solution may be administered to a subject, or applied and mixed with other components of the kit.

[0140] The components of the kit can also be provided in dry or lyophilized form, and the kit can further contain a suitable solvent for reconstituting the lyophilized components. Regardless of the number or type of container, the kit described herein can also include a device to assist in administering the composition to a patient. Such a device can be an inhaler, a nasal spray device, a syringe, a pipette, forceps, a measuring spoon, an eye dropper, or a similar medically approved delivery vehicle.

[0141] In another aspect described herein, an article of manufacture is provided that contains materials useful for treating, preventing, and / or diagnosing the disorders described herein, for example, inhibiting tumor growth. The article of manufacture includes a container and a label or package insert on or associated with the container. Suitable containers include, for example, bottles, vials, syringes, intravenous solution bags, and the like. The containers can be formed from a variety of materials, such as glass or plastic. The container(s) can hold a composition, alone or in combination with another composition, that is effective for treating, preventing, and / or diagnosing a disorder, and can have a sterile access port (for example, the container can be an intravenous solution bag or vial with a stopper that can be pierced by a hypodermic needle).

[0142] The article of manufacture in this embodiment described herein may further include a label or package insert indicating that the composition can be used to treat a particular condition.Alternatively, or in addition, the article of manufacture may further include a second (or third) container that includes a pharma- ceutically acceptable buffer, such as bacteriostatic water for injection (BWFI), phosphate-buffered saline, Ringer's solution, and dextrose solution.It may further include other materials that are desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, and syringes.

[0143] Polypeptides and Nucleic Acids The polypeptide and nucleic acid sequences of genes useful for the methods described herein, such as the gene of Cdc7, are described herein.In some embodiments, the sequences are at least 95, 96, 97, 98, or 99% identical to the sequences described herein or referenced herein by database accession number.In some embodiments, the polypeptide and nucleic acid sequences useful for the methods described herein are 100% identical to the sequences described herein or referenced herein by database accession number. The term "percent identity" in the context of two or more nucleic acid or polypeptide sequences refers to two or more sequences or subsequences that have a certain percentage of nucleotides or amino acid residues that are the same when compared and aligned for maximum correspondence using one of the sequence comparison algorithms described below (e.g., BLASTP and BLASTN or other algorithms available to those skilled in the art) or measured by visual inspection. Depending on the application, the percent "identity" can be over a region of the sequences being compared, e.g., over a functional domain, or over the entire length of the two sequences being compared. For sequence comparison, typically, one sequence serves as a reference sequence to which a test sequence is compared. When using a sequence comparison algorithm, the test sequence and the reference sequence are input into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated. The sequence comparison algorithm then calculates the percent sequence identity of the test sequence(s) to the reference sequence based on the designated program parameters. Optimal alignment of sequences for comparison can be performed, for example, by the local homology algorithm of Smith & Waterman, Adv. Appl. Math. 2:482 (1981), by the homology alignment algorithm of Needleman & Wunsch, J. Mol. Biol. 48:443 (1970), by the search for similarity method of Pearson & Lipman, Proc. Nat'l. Acad. Sci. USA 85:2444 (1988), by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, Wis.), or by visual inspection (see generally, Ausubel et al., Current Protocols in Molecular Biology (2003)).One example of a suitable algorithm for determining percent sequence identity and sequence similarity is the BLAST algorithm, described in Altschul et al., J. Mol. Biol. 215:403-410 (1990). Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information (www.ncbi.nlm.nih.gov). EXAMPLES

[0144] Below are examples of specific embodiments for carrying out the present invention. The examples are provided for illustrative purposes only and are not intended to limit the scope of the present invention in any way. Efforts have been made to ensure accuracy with respect to the numbers used (e.g., amounts, temperatures, etc.), but some experimental error and deviation should, of course, be allowed for.

[0145] The practice of the present invention will employ conventional methods of protein chemistry, biochemistry, recombinant DNA techniques, and pharmacology within the skill of the art, unless otherwise indicated. Such techniques are fully explained in the literature. See, for example, TECreighton, Proteins: Structures and Molecular Properties (WH Freeman and Company, 1993); ALLehninger, Biochemistry (Worth Publishers, Inc., current addition); Sambrook, et al., Molecular Cloning: A Laboratory Manual (2nd Edition, 1989); Methods In Enzymology (S. Colowick and N. Kaplan eds., Academic Press, Inc.); Remington's Pharmaceutical Sciences, 18th Edition (Easton, Pennsylvania: Mack Publishing Company, 1990); Carey and Sundberg Advanced Organic Chemistry 3rd ED. (Plenum Press) Vols A and B (1992). Abbreviation [Table 1]

[0146] Example 1: SRA141 treatment of a mouse AML xenograft model The efficacy of the Cdc7 inhibitor (compound ID, also known as SRA141) alone as monotherapy was tested in xenografts using the acute myeloid leukemia cell line MV-4-11. Female BALB / c mice bearing MV-4-11 xenograft tumors were administered SRA141 at various doses. Sixty 5-6 week old female BALB / C mice were inoculated subcutaneously with MV-4-11 tumor cells. Mice were inoculated with 5.0 × 10 per mouse. 6Cells (mixed with Matrigel® in a 1:1 ratio) were inoculated into 32 mice, which were randomized into 4 groups and treated orally with (i) vehicle control (0.2M HCl / 0.5% MC400) or (ii) SRA141 at 30 or 60 mg / kg BID for 3 weeks or (iii) SRA141 at 120 mg / kg QD for 3 weeks (n=8 per treatment group). Mouse weights were recorded weekly before grouping and mouse condition was recorded daily during treatment. After 21 days of treatment, mice were sacrificed for tumor weight measurement. Tumor growth inhibition was calculated on day 21, the last day of the study.

[0147] As shown in Figure 1A, the mean tumor volume of the four groups on day 21 was 1612.66 mm 3 , 655.68mm 3 , 300.77mm 3 , and 530.83 mm 3 at 30 mg / kg BID, 60 mg / kg BID, and 120 mg / kg QD mg / kg dose levels, respectively. Tumor weights for individual mice were also calculated (FIG. 1B). Thus, SRA141 administration resulted in 59%, 81%, and 67% tumor growth inhibition at 30 mg / kg BID, 60 mg / kg BID, and 120 mg / kg QD mg / kg dose levels, respectively.

[0148] All treatments were tolerated without significant weight loss (Figure 1C). The mean relative body weight change (RCBW) for the four groups on day 21 was 12.11%, 16.39%, 3.18%, and 8.47%, respectively.

[0149] These results demonstrate that SRA141 alone, as a monotherapy, can provide an effective therapy for the treatment of acute myeloid leukemia.

[0150] Example 2: SRA141 treatment of a rat AML xenograft model The efficacy of a Cdc7 inhibitor (compound SRA141) as monotherapy was tested in a rat xenograft model of acute myeloid leukemia (AML) (Figure 2). Female rnu / rnu rats were administered 1 × 10 7 MV-4-11 human acute myeloid leukemia cells were inoculated subcutaneously. MV-4-11 cells were injected in a total volume of 0.1 mL PBS in 1:1 Matrigel®. Rats were cultured until tumors reached 300–400 mm 3 SRA141 treatment was initiated when tumors reached an average size of 100 mg / kg / day. Rats bearing MV-4-11 tumor xenografts were orally administered (i) vehicle control (0.5% CMC-Na / 1% poloxamer 188) or (ii) SRA141 at 75 mg / kg BID for 5 consecutive days of a 7-day cycle for 4 weeks, or (iii) SRA141 at 150 mg / kg QD for 5 consecutive days of a 7-day cycle for 4 weeks (n=10 per treatment group). Tumor volume measurements were taken every other week and body weight measurements were taken every other week until day 15 and then daily until the end of the study. Tumor growth inhibition was calculated on day 42, the final day of the study.

[0151] As shown in Figure 2A, significant tumor growth inhibition (TGI) was observed in rats treated with 75 mg / kg SRA141 (86.1% TGI) and 150 mg / kg SRA141 (86.7% TGI). Additional studies in rats treated with SRA141 at 75 mg / kg observed a TGI of 92% on day 27 of treatment, and 85% on day 34 of treatment. Median tumor volumes were 13247 (n=10) for the vehicle control group, 1838 (n=8) for the 75 mg / kg SRA141 treatment group, and 1764 (n=9) for the 150 mg / kg SRA141 treatment group. Results of treatments per individual rat are shown over the course of treatment (Figure 2C). In particular, treatment with SRA141 at 75 mg / kg BID resulted in one complete regression (tumor volume <13.5 mm3 for three consecutive measurements) and three partial regressions (tumor volume <50% of initial volume for three consecutive measurements). The complete regressions continued until the end of the study. Treatment with SRA141 at 150 mg / kg QD produced two partial regressions in one animal with no measurable tumor at the completion of the study.

[0152] In general, all treatments were well tolerated without significant weight loss (Figure 2B). Three animals were found to have died during the course of the study (n=2 in the 75 mg / kg BID group and n=1 in the 150 mg / kg BID group, respectively). The causes of these deaths were classified as non-treatment related.

[0153] These results demonstrate that SRA141 as a monotherapy can provide an effective therapy for the treatment of AML.

[0154] Example 3: SRA141 treatment of various cancer cell lines The concentration-dependent effect of SRA141 on cell viability was determined in a panel of 235 cancer cell lines using the CellTiter-Glo™ luminescent assay (Promega) with a drug incubation period of 72 hours. After incubation with different concentrations of SRA141, the 50% inhibitory concentration (IC50) was determined in the cancer cell lines using the Cell Titer-Glo® luminescent cell viability assay.

[0155] SRA141 exhibited potent inhibitory activity (IC50<3μM) in various solid tumor cell lines, including those from bladder (5673, RT112 / 84), sarcoma (143B, CADO-ES1, RD-ES, A673), colon and cecum (Colo-205, DLD-1, LS1034, SK-CO-1, SNU-C1), kidney (UO.31), head and neck (CNE-2Z, RPMI-2650), melanoma (A2058, A875), and gastric (HGC-27) lines.

[0156] Significant activity was also observed in blood-derived cell lines. The results of 59 blood cancer cell lines tested are shown in Figure 3A. These results demonstrate that SRA141 alone as a monotherapy can provide an effective therapy for the treatment of blood cancers such as acute myeloid leukemia (Figure 3A, cell lines designated as "C") and chronic eosinophilic leukemia (Figure 3A, cell lines designated as "L"). Significant activity was also observed in all lines (RS411, SUP-B15, Reh), as well as other leukemias and lymphomas (KHYG-1 and JeKo-1).

[0157] A summary of the determined IC50 values ​​is summarized in Figure 3B and categorized by cancer type. Overall, hematological cancer lines showed higher sensitivity than solid tumor lines, and among the latter, colon cancer lines were the most sensitive.

[0158] The differential cytotoxic activity of SRA141 in Colo-205 colon cancer cells versus normal human dermal fibroblasts (NHDFs) was assessed at drug concentrations ranging from 0.03 to 33.3 μM (48 h incubation). After treatment, propidium iodide-labeled cells were analyzed by flow cytometry to determine the percentage of dead cells found in the sub-G1 fraction as a result of apoptosis-mediated DNA fragmentation. As shown in Figure 3C, a striking difference in sensitivity to SRA141 was observed between cancer and normal cells. Notably, 62% of the cancer cells were dead and found in the sub-G1 fraction at compound concentrations between 1 μM and 10 μM. In contrast, less than 10% of normal cells were apoptotic as determined by the sub-G1 fraction, consistent with published reports showing minimal cytotoxicity of non-transformed cells following Cdc7 inhibition (Montagnoli, 2004). Thus, these findings support a potential therapeutic index for SRA141 between tumor and non-transformed tissues.

[0159] As shown in Figure 3C, part B, experiments using two different viability assays demonstrated that SRA141 has comparable or superior in vitro activity in multiple cell lines compared to other Cdc7 inhibitors, TAK-931 and LY-3177833. Taken together, SRA141 demonstrated potent antiproliferative activity in multiple cell lines across several indications.

[0160] The antiproliferative activity of SRA141 was further characterized in seven cell lines (Colo-205, SW620, SNU-398, NCI-H716, MDA-MB-231, NCI-H1573, and SW1116) using four orthogonal assays designed to measure ATP levels (CTG), metabolic activity (CellTiter-Blue (CTB)), cellular DNA content (CyQuant), and esterase activity (Calcein AM). The relative sensitivity of cell lines within each assay format was generally consistent. As shown in Figure 3D, a consistent increase in SRA141 potency was observed with a longer treatment period of 144 h (right column) when compared to 72 h (left column) across all assays and cell lines tested, suggesting that continuous target coverage is necessary for optimal antitumor activity. Monotherapy SRA141 IC50 was also determined by CTG and CyQuant at 144 h after different exposure times to SRA141. As shown in Figure 3E, consistent with previous evaluations, SRA141 potency increased with treatment durations greater than 24 h (24 h left column, 48 h middle column, or 72 h right column).

[0161] Example 4: SRA141 treatment of a patient-derived xenograft mouse model of CRC The efficacy of a Cdc7 inhibitor (compound SRA141) as monotherapy was tested in a patient-derived xenograft (PDX) model of colorectal cancer (CRC). Female nu / nu mice bearing APC and TP53 mutant colon tumor xenografts from CTG-1009 patients were treated with (i) vehicle control (0.1 M HCl / 0.5% MC) or (ii) SRA141 at 120 mg / kg QD for 28 days, or (iii) SRA141 at 150 mg / kg QD for 28 days on 2 consecutive days of a 7-day cycle (n=8 per SRA141 treatment group, n=6 vehicle control group, Champion Study 1250-003). Tumor growth inhibition was calculated on day 32, the final day of the study. Dosing of many animals in the SRA141 120 mg / kg QD and 150 mg / kg QD groups was temporarily interrupted due to weight loss (Figure 4B). These dosing holidays ranged from 1 to 3 days (n = 1 and 3 animals) and 4 to 8 days (n = 7 and 0 animals) in the SRA141 120 mg / kg QD and 150 mg / kg QD treatment groups, respectively.

[0162] As shown in Figure 4A, administration of SRA141 resulted in 49% and 36% tumor growth inhibition at the 120 mg / kg QD and 150 mg / kg QD dose levels, respectively.

[0163] The mean tumor growth inhibition (TGI) observed after SRA141 (120 mg / kg administered QD 5D with a dose holiday ranging from 5-7D and then QD administration) was 49.4% (P=0.0057). SRA141 administered 4 or 6 times during the experiment resulted in a mean TGI of 35.8% on D32 (P=0.0385). The mean TGI observed after SRA141 (120 mg / kg administered QD 5D with a dose holiday ranging from 5-7D and then QD administration) was 49.4% (P=0.0057). Individual TGIs from the mean vehicle tumor volume (TV) were 23.5, 31.3, 47.8, 50.8, 59.9, 63.6, and 68.6%. SRA141 administered 4 or 6 times during the experiment resulted in a mean TGI of 35.8% on D32 (P=0.0385). The three mice with 4 doses had TGIs from the mean vehicle TV of 12.4, 27.2, and 53.2%. The five mice administered 6 times had mean vehicle TV with TGI forms of 15.6, 18.2, 48.2, 65.2, and 71.2%. The results of each treatment per individual mouse are shown over the course of treatment (Figure 5) and at day 32 (Figure 6). Thus, monotherapy with SRA141 resulted in significant tumor growth inhibition (TGI) as determined at D32 of the study.

[0164] In general, all treatments were well tolerated by the end of treatment, with no significant weight loss compared to vehicle (closed circles). Moderate weight loss was observed after the first 5 days of dosing in the 120 mg / kg group (closed squares), but recovered to vehicle levels after a few days off drug (Figure 4B).

[0165] These results demonstrate that SRA141 as a monotherapy can provide an effective therapy for the treatment of colorectal cancer in the APC and TP53 mutant CRC setting.

[0166] Example 5: SRA141 treatment of a patient-derived xenograft rat model of CRC The efficacy of a Cdc7 inhibitor (compound SRA141) as monotherapy was tested in a rat xenograft model of colorectal cancer (CRC) (Figure 7). Female Rowett nude rats were inoculated with 2x10 7 COLO-205 human colon cancer cells were inoculated subcutaneously. All rats were gamma-irradiated (4 Gy) 24 hours prior to tumor cell injection. COLO-205 cells were injected in 0.2 mL of PBS in 1:1 Matrigel®. Female nude rats bearing Colo-205 tumor xenografts were orally administered (i) vehicle control (0.5% CMC-Na / 1% Lutrol F-68) or (ii) 150 mg / kg of SRA141 once daily (QD) for 5 consecutive days of a 7-day cycle for 6 weeks, or (iii) 75 mg / kg of SRA141 twice daily (BID) for 5 consecutive days of a 7-day cycle for 6 weeks (n=7 per treatment group). Tumor growth inhibition was calculated on day 31, the last day all vehicle control animals remained on the study. Tumor volume measurements and body weight measurements were taken every other week.

[0167] As shown in FIG. 7A, administration of SRA141 resulted in significant tumor growth inhibition of 50% and 93% at the 150 mg / kg QD and 75 mg / kg BID dose levels, respectively. Complete tumor regression was observed in 4 / 7 rats. Furthermore, complete tumor regression (defined as no measurable tumor for three consecutive measurements) was observed in four of seven animals, and partial regression (tumor volume <50% of initial volume for three consecutive measurements) was observed in one of seven animals at the 75 mg / kg BID dose. All four complete regressions continued until the completion of the study.

[0168] As shown in Figure 7B, a tumor SRA141 concentration of approximately 1.2 μM resulted in an approximately 50% reduction in phosphorylated MCM2 (serine 53) compared to vehicle-treated rats, suggesting that selective inhibition of Cdc7 is not compatible with tumor cell survival. Rats bearing Colo-205 tumors were treated with a single dose of SRA141 or vehicle, and tumors were collected 12 hours later. Tumor homogenates prepared from three animals per treatment group were analyzed by LC / MSMS or Western blot. The results demonstrate that SRA141 as a monotherapy can provide an effective therapy for the treatment of colon cancer.

[0169] Example 6: Combination of SRA141 with additional antitumor agents To confirm the effectiveness of Cdc7 inhibitors in combination with antitumor agents to sensitize cancer cells, experiments were performed in human cancer cells.

[0170] Combination evaluation method: Combination screening was performed using a co-treatment dosing schedule of SRA141 and partner compound. Both enhancer (SRA141) and enhancer (partner compound) were added at time zero (0 h). Cells were exposed to SRA141 and enhancer for the entire 72 h treatment period. All data points were collected via an automated process, subject to quality control, and analyzed using proprietary software. Assay plates were accepted if they passed the following quality control criteria: relative raw values ​​were consistent throughout the experiment, Z-factor scores were greater than 0.6, and untreated / vehicle controls behaved consistently across the plate.

[0171] Growth inhibition (GI) was utilized as a measure of cell proliferation. The GI percentage is calculated by applying the following test and formula:

number

[0172] Inhibition as a measure of cell viability: An inhibition level of 0% represents no inhibition of cell growth due to treatment. 100% inhibition represents no doubling of cell number during the treatment window. Both cytostatic and cytotoxic treatments can result in a 100% inhibition rate. The inhibition percentage is calculated as follows: I=1-T / U, where T is treated and U is untreated.

[0173] Synergy score analysis To measure the combination effect beyond the Loewe additive degree, a scalar measure was used to characterize the strength of the synergistic interaction called the synergy score. The synergy score is calculated as follows: Synergy score = logf X logf Y Σmax(0,I data )(I data -I Loewe )

[0174] The fractional inhibition of each component agent and combination point in the matrix is ​​calculated relative to the median of all vehicle-treated control wells. The synergy score equation integrates the experimentally observed activity volume at each point in the matrix over a model surface that is numerically derived from the activity of the component agents using the Loewe model for additivity. Additional terms in the synergy score equation (above) are used to normalize for the various dilution factors used for the individual agents and allow for comparison of synergy scores across experiments. The inclusion of positive inhibition gating or Idata multipliers removes noise around the zero effect level and biases the results of synergistic interactions that occur at high activity levels. Combinations with higher maximum growth inhibition (GI) effects or that are synergistic at low concentrations have higher synergy scores. These combinations with synergy scores that statistically precede the baseline self-crossing value can be considered synergistic. The magnitude of the GI effect can be linked to the growth rate of cells, which varies for each cell line tested.

[0175] Potency shifts were assessed using isobolograms, which demonstrate how much less drug is needed in combination to achieve a desired effect level compared to the single-agent doses required to reach that effect. Isobolograms were plotted by identifying the concentration loci that correspond to passing through the indicated inhibition levels. This is done by finding the intersection points of each single-agent concentration in the dose matrix across the concentrations of the other single agents. In effect, each vertical concentration C Y is the response surface Z(C X , C Y ) the horizontal concentration C combined with the vertical dose that gives the selected effect level XThese concentrations are then connected by linear interpolation to generate the isobologram display. For synergistic interactions, the isobologram contour falls below the additivity threshold and approaches the origin, whereas antagonistic interactions lie above the additivity threshold. Error bars represent the uncertainty arising from the individual data points used to generate the isobologram. The uncertainty at each intersection point is estimated from the response error using the binomial, Z-σ Z (C X , C Y ) and Z+σ Z (C X , C Y ) is I cut The concentration at which the Z is the standard deviation of the residual error on the effect scale.

[0176] Synergy Score Analysis: Loewe Volume Score Analysis The Loewe Volume score is used to assess the overall magnitude of a combination interaction beyond the Loewe Additivity Model. The Loewe Volume is particularly useful in distinguishing between synergistic increases in phenotypic activity (positive Loewe Volume) and synergistic antagonism (negative Loewe Volume). When antagonism is observed, as in the current dataset, the Loewe Volume is assessed to examine whether there is any correlation between the antagonism and the specific drug target activity or cellular genotype. This model defines additivity as a non-synergistic combination interaction where the combination dose matrix surface cannot distinguish between itself and any of the drugs intersecting it. Additivity calculations are calculated as (X / X I )+(Y / Y I )=1 Loewe where X I and Y Iis the single agent effective concentration for the observed combination effect I. For example, if 50% inhibition is achieved by 1 μM drug A or 1 μM drug B separately, then a combination of 0.5 μM A and 0.5 μM B should also be inhibited by 50%. Activity observed beyond the Loewe Additive Level identifies a synergistic interaction. For the present analysis, we compared the empirically derived combination matrix with their respective Loewe Additive Level models constructed from experimentally collected single agent dose response curves. This summary of excess additivity across the dose response matrix is ​​referred to as the Loewe Volume. A positive Loewe Volume suggests synergy, whereas a negative Loewe Volume suggests antagonism. As previously mentioned, the synergy score is a positive gate value and cannot be used to measure potential antagonism.

[0177] To confirm the efficacy of Cdc7 inhibitors in combination with antitumor drugs to kill cancer cells, experiments were performed in Colo-205 colon adenocarcinoma cells and acute myeloid leukemia cells with either sequential treatment in combination with antitumor drugs or simultaneous treatment with the Cdc7 inhibitor SRA141. To confirm the efficacy of Cdc7 inhibitors to sensitize cancer cells when used in combination with inhibitors of the mammalian target of rapamycin (mTOR) pathway, inhibitors of DNA polymerase, inhibitors of receptor tyrosine kinases (RTKs), inhibitors of the mitogen-activated protein kinase pathway (MAPK), or inhibitors of the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway, human Colo-205 colon adenocarcinoma cells were sequentially treated with SRA141 and then with everolimus, aphidicolin, or midostaurin as single agents (Figure 8). Flasks of Colo-205 cells were pretreated with SRA141 (1 μM and 200 nM) and DMSO control for 48 h, the cells were washed and plated in 384-well plates, the plates were incubated for 6 h and then treated with everolimus, aphidicolin or midostaurin 6 h after plating as single agents. After 72 h, ATP levels were measured using ATPlite. Pretreatment of COLO-205 cells with SRA141 showed a shift in potency of the enhancer towards increased sensitivity to midostaurin, with an EC of 3.19 with 200 nM SRA141 pretreatment compared to DMSO pretreatment. 50 A fold change of 4.60 EC for aphidicolin was observed with 1 μM SRA141 pretreatment compared to DMSO pretreatment. 50 A fold change of 3.3 EC for everolimus was observed with 200 nM SRA141 pretreatment compared to DMSO pretreatment. 50 Fold changes were observed.

[0178] To confirm the efficacy of the combination of Cdc7 inhibitors with MAPK or PI3K pathway inhibitors to kill cancer cells and to treat cancer, Colo-205 cells were treated simultaneously with MAPK pathway inhibitor, trametinib, PI3K pathway inhibitor, copanlisib, and antimetabolite (antifolate), methotrexate (Figures 9 and 10A). Cells were seeded in 384-well plates on day 0, the plates were incubated for 24 hours, the cells were treated with trametinib and copanlisib in combination with SRA141, and 72 hours later, ATP levels were measured using ATPlite. A strong synergistic effect was observed in COLO-205 cells by simultaneous combination treatment with MAPK and PI3K pathway inhibitors and antifolate antimetabolite, methotrexate.

[0179] To confirm the efficacy of Cdc7 inhibitors to sensitize cancer cells when used in combination with inhibitors of the mitogen-activated protein kinase pathway (MAPK), regulators of the retinoid pathway, regulators of apoptosis, PARP inhibitors, or inhibitors of the mammalian target of rapamycin (mTOR) pathway, human acute myeloid leukemia cells, MOLM-13 cells, were sequentially treated with SRA141 followed by trametinib or bexarotene as single agents (Figure 8). Flasks of MOLM-13 cells were pretreated with SRA141 (1 μM and 200 nM) and DMSO control for 48 h, cells were washed, plated in 384-well plates, left on the plate and incubated for 6 h, and then treated with trametinib or bexarotene for 6 h after plating as single agents. After 72 h, ATP levels were measured using ATPlite. For trametinib, there was an EC of 2.63 with 200 nM SRA141 pretreatment compared to DMSO pretreatment. 50 A fold change was observed for bexarotene, with an EC of 2.63 with 200 nM SRA141 pretreatment compared to DMSO pretreatment. 50 A fold change was observed for everolimus with 3.25 EC with 200 nM SRA141 pretreatment compared to DMSO pretreatment. 50 Fold changes were observed.

[0180] To confirm the efficacy of Cdc7 inhibitors in combination with retinoid pathway regulators, apoptosis regulators, or PARP inhibitors to kill cancer cells and for use as combination therapy for the treatment of cancer, human MOLM-13 and KG-1 cells were simultaneously treated with the PARP inhibitor BMN673, the apoptosis regulator ABT-199, the retinoid pathway regulator, bexarotene, or the retinoid pathway regulator tretinoin (Figures 9 and 10A). Cells were seeded into 384-well plates on day 0 and left to incubate for 24 hours, cells were dosed with BMN673, ABT-199, bexarotene, or tretinoin in combination with SRA141, and after 72 hours, ATP levels were measured using ATPlite. MOLM-13 cells showed strong synergistic effects with BMN673 (PARP inhibitor), ABT-199 (BCL-2 inhibitor), bexarotene, and tretinoin (retinoid pathway regulator). These results confirm that combination therapy including the use of Cdc7 inhibitors in combination with mTOR pathway inhibitors, DNA polymerase inhibitors, and receptor tyrosine kinase inhibitors, as well as MAPK pathway inhibitors, retinoid pathway regulators, apoptosis regulators, or PARP inhibitors, either sequentially or simultaneously with Cdc7 inhibitors, is effective in killing cancer cells, and indicate that administration of Cdc7 inhibitors in combination with mTOR pathway inhibitors, DNA polymerase inhibitors, and receptor tyrosine kinase inhibitors, as well as MAPK pathway inhibitors, retinoid pathway regulators, apoptosis regulators, or PARP inhibitors is an effective cancer treatment regimen.

[0181] To confirm the efficacy of the combination of Cdc7 inhibitors with the replicative stress-inducing antitumor agent gemcitabine, human HT-29 colon adenocarcinoma cells were treated for 96 h with increasing concentrations of gemcitabine (0.037-1 µM). Data shown in Figure 10B demonstrate that gemcitabine doses greater than 100 nM resulted in nearly 100% growth inhibition of treated cells. Furthermore, the addition of SRA141 at concentrations of either 1.1 µM or 3.3 µM substantially reduced the inhibitory effect of gemcitabine.

[0182] Example 7: Potency and selectivity of SRA141 in biochemical assays Inhibition of Cdc7 by SRA141 was measured using an in vitro kinase assay.

[0183] As shown in Figure 11A, SRA141 demonstrated potent inhibition of Cdc7 in an in vitro biochemical assay (IC50=4nM). Preincubation of SRA141 with the Cdc7 enzyme for 1 hour prior to the assay moderately improved the compound's potency (IC50=1.4nM), confirming the potent inhibition of Cdc7 with potentially favorable inhibitor binding kinetics. These findings are consistent with rapid dilution studies showing a long residence time (t1 / 2=215 min) and slow dissociation kinetics (Koff=0.0032 at 5nM) for SRA141 binding to Cdc7, as shown in Figure 11B.

[0184] The selectivity of SRA141 for Cdc7 was evaluated using the DiscoverX kinome screening assay, which contains approximately 430 native and mutant kinases. Minimal off-target kinase activity was detected at a compound concentration of 500 nM. The selectivity of SRA141 for Cdc7 was compared to TAK-931. The results of the kinome screening assay (Figure 12) demonstrate that SRA141 has less off-target activity compared to TAK-931 at a compound concentration of 500 nM.

[0185] Example 8: Effects of SRA141 on cellular substrates of several cell cycle kinases Colo-205 cells were treated with SRA141 (at concentrations ranging from 0.033 to 3.3 μM) for 8 to 24 h with subsequent assessment of the phosphorylation status of downstream targets of Cdc7 (MCM2, Ser40 / 41 and Ser53) and the putative off-target kinases CDK8 (STAT1, Ser727), CDK7 and 9 (RNA polII, Ser2), LATS2 (YAP1, Ser127), and levels of MCL-1 known to be indirectly regulated by CDK9 (Gregory, 2015).

[0186] MV411 cells were also treated with SRA141 in a dose-dependent manner (at concentrations ranging from 0.5 to 3.3 μM) and then assessed for the phosphorylation status of MCM2 at Ser40 / 41 and Ser53.

[0187] As shown in Figure S13, Cdc7 levels were unchanged in these studies, but phosphorylation of its target MCM2 at Ser40 / 41 and Ser53 was decreased in a concentration-dependent manner starting at 0.033 μM (Colo-205) and 0.5 μM (MV411), demonstrating robust on-target inhibition in cells.

[0188] There was no significant change in the phosphorylation state (or protein levels of MCL-1) for any of the cellular substrates at concentrations of SRA141 ~1 μM. Minimal inhibition of STAT1, YAP1, and MCL-1 was observed at 3.3 μM, but the coincident reduction in total protein levels suggests that these findings may have been due to SRA141-mediated cell death.

[0189] Together, these data confirm the potency and selectivity of SRA141 in a cellular setting.

[0190] Example 9: Activity of SRA141 in AML three-dimensional (3D) cultures The activity of SRA141 was investigated in in vitro and ex vivo three-dimensional (3D) cultures prepared from three AML cell lines (EOL-1, Molm-16, and MV-4-11) and three AML PDX models (AM5512, AM7440, and AM7577), respectively. Tumor cultures were treated with SRA141 (0.08-33 μM) for 5 days. SRA141 showed potent anti-cellular activity (IC50 range 0.15-1.6 μM) in five of the six models, with reduced activity observed in the AM5512 preparation (IC50=3.2 μM, Table 1). This latter model was also relatively resistant to cytarabine and cisplatin (IC50>8.9 μM). [Table 2]

[0191] The antiproliferative activity of SRA141 (0.3-5 μM) was also evaluated in additional 3D growth studies performed in methylcellulose growth matrices using normal human myeloid (n=3) and AML-blast precursors incubated for 14 days.

[0192] The mean SRA141 IC50 value for normal bone marrow preparations was 0.25 μM, whereas the mean IC50 value for AML samples was approximately 0.16 μM (resistant progenitor sample AML810 was censored, Table 2). The positive control, cytosine arabinoside (Ara C), had an equipotential IC50 value (approximately 0.004 μM) for both normal bone marrow and AML blast progenitor samples. Each sample [(Primary AML IC 50 )÷(BMNC control IC 50 Therapeutic indices were also calculated for AML141, AML200, AML917, AML915, AML190, and AML717. As shown in Table 2, five of the nine primary AML samples responded to SRA141 at TI (AML200, AML917, AML915, AML190, and AML717), whereas only two of the nine samples responded to Ara-C at TI (AML200 and AML250).

[0193] Taken together, these data demonstrate that SRA141 has potent cytotoxic activity in AML 3D cultures with a potential therapeutic index over normal myeloid precursors. [Table 3]

[0194] Example 10: Durability of Cdc7 inhibition by SRA141 in cultured cells The durability of drug-induced Cdc7 inhibition was investigated in Colo-205 cells treated with two concentrations of SRA141 (0.1 μM and 1 μM) for 48 h, followed by either immediate cell harvest or removal of the drug incubation followed by an additional 24 h incubation before cell harvest. Phosphorylation of MCM2 at Ser53, a target site for Cdc7 activity, was compared between the two conditions.

[0195] As shown in Figure 14, data from this study showed recovery of Cdc7 activity by 24 hours after compound washout at a drug concentration of 0.1 μM, while prolonged pMCM2 inhibition was observed 24 hours after washout at the higher incubation concentration (1 μM). These results are consistent with previous biochemical assays that demonstrated slow target off-rates resulting in prolonged enzyme inhibition.

[0196] Example 11: SRA141 Cell Cycle Sensitivity Analysis The sensitivity of various phases of the cell cycle to SRA141 treatment was determined in Colo-205 cells synchronized with a double thymidine block. Upon block release, SRA141 (1 μM) was added when cells reached either S or M phase.

[0197] As shown in Figure 15, flow cytometry analysis of propidium iodide-labeled cells demonstrated that a sub-G1 population representing apoptotic cells accumulated as they progressed through M-phase provided that cells were treated with SRA141 during the preceding S-phase (Figure 15A), but not if treatment was initiated after completion of S-phase (the beginning of M-phase) (Figure 15B). When SRA141 was first added at M-phase, accumulation of sub-G1 was delayed and cells had to progress through the subsequent S-phase in the presence of SRA141 before showing signs of apoptosis.

[0198] These data support the hypothesis that inhibition of Cdc7 function during S phase, replication origin firing most likely mediated by MCM2 / MCM4 phosphorylation, causes cells to enter mitosis with underreplicated DNA and leads to the induction of apoptotic cell death.

[0199] As shown in Figure 15C, Colo-205 cells treated with 0.1 μM SRA141 for 48 hours were evaluated for cell cycle and DNA damage markers by Western blot. The results demonstrate the presence of mitotic markers in the G2 / M phase after treatment with SRA141. These results are consistent with data obtained by using high content imaging demonstrating that Colo-205 and SW620 cell populations treated with SRA141 for 48 hours have an accumulation of cells in mitosis (Figure 15D). The percentage of cells in mitosis is greater in the populations treated with SRA141 compared to other Cdc7 inhibitors.

[0200] Example 12: In vitro cellular gene susceptibility analysis Analysis of SRA141 sensitivity of a panel of 235 cell lines demonstrated that colon cancer was among the most sensitive solid tumor lines (Figure 16). Furthermore, bioinformatics analysis of the genomic and methylation patterns of the 235 cell lines showed that mutations in FAT1 correlated with SRA141 sensitivity. Given the role of FAT1 in the Wnt signaling pathway, which is commonly altered in colon cancer, we further examined the correlation between the sensitivity of 16 colon cancer lines and the presence of mutations in two other Wnt pathway genes, APC and FAT4.

[0201] The results show that APC mutations, commonly found in chromosomally unstable (CIN) colon tumors, were associated with increased sensitivity to SRA141 (p=0.04, FIG. 16). Although FAT4 mutations were not determined to be statistically correlated with SRA141 sensitivity, the three most sensitive lines were found to harbor FAT4 mutations. These preliminary data support the use of SRA141 in CIN colon cancer.

[0202] Example 13: Colo-205 colon xenograft study (mouse) Female BALB / c mice bearing Colo-205 tumor xenografts were orally dosed with (i) vehicle (0.2 M HCl / 0.5% MC400) or (ii) SRA141 at 30 or 60 mg / kg BID for 17 days, or (iii) SRA141 at 120 mg / kg QD for 17 days (n=8 per treatment group). Tumor growth inhibition was calculated on day 16, the final day of the study.

[0203] All treatments were tolerated, but due to excessive weight loss (>15% loss), dosing was temporarily suspended for 2 days in 2 mice from the SRA141 60 mg / kg BID and for 1 and 5 days in 2 mice from the 120 mg / kg QD treatment group.

[0204] As shown in Figure 17, SRA141 administration resulted in 15%, 58%, and 37% tumor growth inhibition at dose levels of 30 mg / kg BID, 60 mg / kg BID, and 120 mg / kg QD, respectively. These preliminary data support the use of SRA141 in colon cancer.

[0205] Example 14: SW620 colon xenograft study (mouse) Female BALB / c mice bearing SW620 tumor xenografts were orally dosed with (i) vehicle (0.1 M HCl / 0.5% MC400) or (ii) SRA141 at 60 mg / kg three times on four consecutive days (TID) followed by a two-day dosing holiday for 21 days, or (iii) SRA141 at 120 mg / kg QD for 21 days (n=10 per treatment group). Tumor growth inhibition was calculated on day 21, the final day of the study. All vehicle control animals remained on study at day 21.

[0206] Four of 10 mice treated with SRA141 at 60 mg / kg TID experienced a maximum weight loss of more than 20%. Dosing of these animals was discontinued until weight loss recovered to less than 20%. None of the mice treated with SRA141 at 120 mg / kg QD met the 20% weight loss threshold.

[0207] As shown in Figure 18, SRA141 administration resulted in 78% and 73% tumor growth inhibition at 60 mg / kg TID and 120 mg / kg QD, respectively. These preliminary data support the use of SRA141 in colon cancer.

[0208] Example 15: MV-4-11 human leukemia whole body survival study Female NOD SCID mice inoculated intravenously with MV-4-11 cancer cells were administered (i) vehicle control (0.1 M HCl / 0.5% MC400, orally) or (ii) SRA141, initially at 60 mg / kg BID for 5 consecutive days of a 7-day cycle from days 0 to 21, and then, due to significant weight loss, at 40 mg / kg BID on the same schedule from days 22 to 73 (n=10 per treatment group). Given the systemic nature of the cancer model, survival was the only efficacy endpoint in this study.

[0209] In general, treatment with SRA141 was tolerated based on the weight loss data: 1 in 10 SRA141-treated mice experienced greater than 20% weight loss.

[0210] Five animals in the SRA141 treatment group were found to have died on days 17 and 18 of the study, likely due to technical error or tolerability rather than disease progression. The median survival of all animals, including those with early deaths, was 66 and 35 days in the vehicle and SRA141 treatment groups, respectively, and exceeded 99 days in the SRA141 treatment group in which early deaths were censored. Thus, the increased survival of the censored treatment group supports the use of SRA141 in the treatment of leukemia.

[0211] Example 16: A20 immunocompetent lymphoma xenograft model (mouse) Immunocompetent female BALB / c mice bearing A20 tumor xenografts were dosed with (i) control (PBS, intraperitoneally) or (ii) 120 mg / kg of SRA141 orally, n=8 animals per group). Dosing occurred on days 0-4, 7-11, and 14-18. Tumor growth inhibition was calculated on day 23, the final day of the study.

[0212] In general, treatment with SRA141 was well tolerated. One animal experienced more than 20% weight loss and was subsequently euthanized.

[0213] As shown in Figure 19, SRA141 administration resulted in 59% tumor growth inhibition. These preliminary data support the use of SRA141 in lymphoma.

[0214] Example 17: MDA-MB-486 Breast Xenograft Study (Mouse) Female CB-17 SCID mice bearing MDA-MB-486 breast tumor xenografts were orally dosed with (i) vehicle control (0.1 M HCl / 0.5% MC400) or (ii) SRA141 at 30 or 60 mg / kg BID for 5 weeks (n=10 per treatment group). Tumor growth inhibition was calculated on day 35, the final day of the study.

[0215] Vehicle control and SRA141 at 30 mg / kg BID treatment were well tolerated. Six of 10 mice treated with SRA141 at 60 mg / kg BID experienced maximum weight loss of more than 20%. Dosing of these animals was temporarily suspended on days 18 and 19, and one animal was euthanized due to prolonged weight loss.

[0216] As shown in Figure 20, SRA141 administration resulted in 26% and 53% tumor growth inhibition at 30 mg / kg BID and 60 mg / kg BID, respectively. These preliminary data support the use of SRA141 in breast cancer.

[0217] Example 18: PK / PD evaluation of mouse SW620 colon xenograft model The effect of SRA141 treatment on tumor phospho-MCM2 (pMCM2), a direct substrate of Cdc7, and a downstream marker of Cdc7 inhibition, was determined in mice bearing SW620 xenografts. Changes in pMCM2 were correlated with SRA141 concentrations in tumor and plasma over 48 hours after drug administration to construct a primitive PK / PD model.

[0218] Specifically, female BALB / c mice bearing subcutaneous SW620 tumors were administered a single oral dose of 30, 60, or 120 mg / kg SRA141 (n=15 per group). Control animals were administered vehicle (0.1 M HCl / 0.5% MC400, n=10). At 2, 4, 8, 24, and 48 hours after treatment, three animals from each group (n=2 for control) were terminated and plasma and tumors were sampled for analysis.

[0219] As shown in Figure 21, pMCM2 levels decreased after a single SRA141 dose, peaking at 2-4 hours for the 30 mg / kg-60 mg / kg doses and 2-8 hours for the 120 mg / kg dose (pMCM2 levels shown in Figure 21A, % inhibition quantified and normalized to actin in Figure 21B). Maximum SRA141 plasma concentrations of approximately 1, 1.5, and 2 μg / mL were also observed 2-4 hours after dosing for the 30 mg / kg, 60 mg / kg, and 120 mg / kg doses. Tumor concentrations of the drug were similar. Correlation of PK and PD data from this study suggested that circulating plasma and intratumoral tissue concentrations of approximately 1.1 μM were required to inhibit pMCM2 by 50%.

[0220] Example 19: PK / PD evaluation of the rat Colo-205 colon xenograft model Tumor inhibition of pMCM2 following SRA141 treatment was also determined in female Rowett nude rats bearing subcutaneous Colo-205 tumors. Twelve hours after a single oral dose of SRA141 (75 or 150 mg / kg), animals were terminated and tumors were sampled for analysis (n=3 per group). Control animals were administered the same vehicle used in the Colo-205 rat model (see Example 5, n=3 per group). SRA141 tumor concentrations of approximately 0.5 μg / mL and 0.9 μg / mL were observed 12 hours after administration of the 75 mg / kg and 150 mg / kg doses, respectively. Twelve hours after a single dose of SRA141, pMCM2 was inhibited by approximately 50%-60% of control (Figure 22). These results suggest that an intratumoral tissue concentration of 1 μM is sufficient to inhibit MCM2 phosphorylation (pMCM2) by 50%.

[0221] Example 20: In vivo non-clinical pharmacokinetic summary In vitro distribution studies showed that SRA141 bound highly to human and rat plasma proteins (>90%), whereas moderate binding was observed in mouse and canine matrices (58%-77%). In addition, SRA141 did not preferentially fractionate to erythrocytes in any species matrix.

[0222] In vitro metabolic studies performed in preclinical and human hepatocytes indicate good metabolic stability of SRA141 in rat, dog, and human preparations. Eleven metabolites were identified across species, six of which occurred in the human matrix. One human-specific metabolite was identified, but only at trace levels. Mouse, rat, and dog hepatocyte metabolite profiles contained all other human metabolites.

[0223] At clinically relevant concentrations, SRA141 demonstrated in vitro time- and metabolism-dependent inhibition of CYP3A4 / 5 (IC50 = 6.2-6.7 μM), as well as in vitro inhibition of human organic anion transporters OATP1B1, OATP1B3, and OAT3 (>50% inhibition at 10 μM). Taken together, these in vitro CYP and transporter inhibition data suggest that SRA141 may potentially alter the metabolism and / or distribution of co-administered drugs known to be substrates for this CYP isoform or these transporters.

[0224] SRA141 (presented as a free base suspension) demonstrated moderate absolute oral bioavailability (F%) in fasted mice, rats and dogs ranging from 31% to 54%, along with an apparent lower oral bioavailability in monkeys (F%=1%-33%). Presentation as the dihydrochloride salt in suspension did not appear to significantly increase exposure in any species. Further studies in dogs suggested that absolute oral bioavailability of the dihydrochloride salt in suspension could be improved following fed administration. However, in another study in dogs, moderate absolute oral bioavailability was noted following administration of two proposed clinical drug product capsule presentations (F%=41%-62%), and fed state did not appear to have a notable effect on oral bioavailability. Systemic exposure (Cmax, AUC) following oral administration generally increased with increasing dose, but in a less than dose-proportional manner.

[0225] Non-tumor bearing female nude rats were orally treated with SRA141 (n=3 per route) at 50 mg / kg (QD x 12 days) or 100 or 150 mg / kg (5 days on / 2 days off / 5 days on). Vehicle was 0.5% CMC-Na / 1% lutrol in water. SRA141 plasma concentrations were determined by LC-MS / MS after the last dose. As shown in Figure 23, systemic exposure increased as the oral dose increased from 50 mg / kg to 150 mg / kg.

[0226] Example 21: In vivo non-clinical toxicity summary Toxicity studies evaluating SRA141 were conducted in rats and dogs after single and repeated oral dosing for up to four cycles (5 days on / 2 days off per cycle). In addition, the potential genotoxicity of SRA141 was evaluated in vitro. A summary of findings is shown in Table 3. [Table 4]

[0227] Findings from repeated-dose toxicity studies in rats and dogs indicate that the potential target organs for SRA141-related toxicity are the gallbladder / biliary system, lymphoid tissues (spleen, thymus, lymph nodes and GALT), bone marrow, liver, kidneys, male and female reproductive tracts, peripheral leukocytes, and salivary glands, with dogs appearing to be the most sensitive species.

[0228] Effects on the biliary system were consistently observed in both rats and dogs with a high incidence. However, these biliary changes were generally minimal to mild and partial (biliary hyperplasia in both species) or fully reversible (gallbladder in dogs, tissue absent in rats). Furthermore, drug-induced biliary findings in animals do not reliably predict similar findings in humans (Hailey, 2013; MacDonald, 2004).

[0229] Biliary and Kupffer cell changes were the only findings observed after repeated administration of SRA141 to rats for 28 days, and were accompanied by hematological and clinical chemistry changes. However, dose-ranging studies in rats identified changes in other organs and tissues, including the liver (hepatocellular degeneration), spleen (red blood cell depletion) and stomach (inflammation and epithelial hyperplasia). It is unclear why comparable findings were not observed in the 28-day study in rats, but the cyclic administration of the drug in the pivotal study may have contributed to the different toxicological outcomes. The similarity of some tissue changes beyond the biliary system in the 7-day rat study and the 28-day dog ​​study, despite differences in formulation, dose and dosing period, suggests that dogs may be more sensitive than rats to SRA141.

[0230] Although alterations in the junctional salivary glands are deemed deleterious to affected dogs, the low incidence and absence of comparable salivary glands in humans makes this potential target of uncertain clinical relevance in humans. Similarly, the small magnitude and reversibility of changes in lymphoid tissues, along with cyclic changes in peripheral leukocytes associated with intermittent dosing cycles, were deemed not deleterious, and these changes may be interrelated and represent transient tissue and peripheral blood changes in leukocyte trafficking. The potentially deleterious reduced cellularity of bone marrow may also be related to this proposed change in leukocyte trafficking. Although the reduction in thymus was more severe than the changes in other lymphoid tissues, this tissue change may be partially or completely secondary to stress and not reflect direct SR141-related toxicity.

[0231] In the 28-day dog ​​study, there appeared to be potential sex differences with males being more affected by changes in the gallbladder, renal tubules, and bone marrow, however, the small numbers of animals in each study group and the low magnitude of sex differences preclude a definitive determination of specific sex differences in tissue responses.

[0232] SRA141 was negative for both mutagenicity and follicle growth potential in in vitro bacterial reverse mutation and human lymphocyte chromosome aberration assays.

[0233] In conclusion, the results of these studies indicate that toxicity findings following administration of SRA141 are generally monitorable in clinical settings, where supportive care is available, and / or are less relevant in advanced oncology study populations. Specifically, the MTD and highest non-severe toxic dose (HNSTD) following a 5-day on / 2-day off dosing schedule for 4 weeks were considered to be 100 mg / kg / day (600 mg / m2 / day) and 10 mg / kg / day (200 mg / m2 / day) in rats and dogs, respectively.

[0234] Example 22: SRA141 CRC Clinical Trial Clinical trials will be conducted to confirm the efficacy of SRA141 monotherapy in treating cancer in patients with metastatic CRC of enriched CIN phenotype by excluding patients with MSI-H status, but in some cases other cancers with high chromosomal instability will be explored in the future.

[0235] The starting human equivalent dose for oncology clinical trials is typically one tenth of the severely toxic dose in 10% of rodents (STD10) or one sixth of the highest dose not causing severe toxicity in non-rodents (HNSTD), whichever is lower (ICH S9, 2009). Data from GLP central toxicity studies (see Example 21) showed a maximum tolerated dose (MTD as a surrogate for STD10) of 100 mg / kg / day (600 mg / m2 / day, the highest dose tested) in rats, and a HNSTD of 10 mg / kg / day (200 mg / m2 / day) in dogs as a more sensitive species. Therefore, a human equivalent dose (HED) of 33.3 mg / m2 / day (0.90 mg / kg / day) is utilized, which is equivalent to an absolute dose of 54 mg (for a 60 kg patient). To further ensure subject safety, a lower starting dose of SRA141 of 10 mg administered orally will be used.

[0236] The clinical dosing schedule is consistent with the preclinical dosing schedule that demonstrated antitumor activity, i.e., 5 days on / 2 days off. SRA141 is supplied in a hydroxypropyl methylcellulose (HPMC) capsule. SRA141 capsules are taken on an empty stomach (subjects fast for at least 2 hours prior to dosing and 1 hour after dosing) unless otherwise indicated by the sponsor based on additional data.

[0237] Dose Escalation Phase A dose escalation phase will be conducted. 15-50 subjects with metastatic CRC will be enrolled. An accelerated titration design will be utilized. Cohorts, initially consisting of single subjects, will receive escalating doses of SRA141. The initial dose escalation will proceed with escalations up to 100% as long as deemed clinically appropriate based on the emerging safety profile. If SRA141-related National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) grade 2 or higher toxicity is observed during cycle 1 in a particular cohort, that cohort will be expanded to 3-6 subjects, with subsequent dose level cohorts following a rolling-6 design. The dose of SRA141 will then be escalated in increments determined after review of all available safety data. For example, if an alternative schedule is pursued, the dose of SRA141 will be escalated until the MTD is identified, unless otherwise determined by the sponsor. Dose escalation with the alternative schedule may be initiated at any time and performed in parallel with or in place of continued dose escalation on the original schedule.

[0238] The DLT evaluation period is from the first dose on day 1 of cycle 1 to the end of the first cycle of treatment. In some cases, subjects who are not evaluable for DLT evaluation, e.g., do not complete the DLT evaluation period for reasons other than intolerance / toxicity of SRA141, will be replaced.

[0239] A DLT is defined as any of the following events if considered highly or probably related to SRA141 (per NCI-CTCAE v4.03): Grade 4 neutropenia, anemia, or thrombocytopenia lasting >7 days despite withholding dosing and / or providing supportive care, Grade 4 febrile neutropenia, Grade ≥ 3 thrombocytopenia accompanied by Grade ≥ 3 hemorrhage, - Grade ≥ 3 non-hematologic toxicity, with the exception of grade 3 nausea, vomiting, and / or diarrhea in the absence of appropriate prophylaxis or treatment, fatigue, and transient and asymptomatic grade 3 laboratory abnormalities. (See protocol for details) - Inability to receive 75% of the planned dose of SRA141 due to intolerance or toxicity.

[0240] Dose-limiting toxicity will be considered for the purposes of dose escalation decisions, but if cumulative toxicity is evident, it will be considered when deciding on the next dose level for escalation or RP2D.

[0241] Dose expansion phase A dose expansion phase will also be conducted. Approximately 30 subjects with metastatic CRC whose tumors are not of known microsatellite instability-high (MSI-H) status will be enrolled in a single expansion cohort to further characterize the safety profile and evaluate preliminary efficacy. In some cases, enrollment of the expansion cohort will begin prior to the determination of the MTD or RP2D if there is evidence of antitumor activity or if SRA141 plasma concentrations reach a minimum efficacy threshold based on new nonclinical data. SRA141 will be administered at the proposed RP2D and scheduled based on the results of the dose escalation phase of the study. In some cases, the RP2D of SRA141 is equal to or less than the MTD. Alternatively, if enrollment begins prior to the determination of the RP2D, SRA141 will be initially administered at the highest dose cleared during the dose escalation phase at the time of enrollment of each subject. If a higher dose level of the same schedule is determined to be safe in the escalation cohort, in some cases, subjects will be escalated to the higher dose level.

[0242] methodology SRA141 treatment will be administered orally once daily on a 5-day on / 2-day off schedule in 28-day cycles in the initial cohort(s). Alternative dosing schedules will be considered based on emerging safety and tolerability data.

[0243] The study consists of screening, treatment, safety follow-up (SFU) and long-term follow-up. In some cases, the treatment period will continue until one of the predefined criteria is met, including disease progression, unacceptable toxicity, and pregnancy.

[0244] Screening and baseline evaluations will be performed for WOCBP subject demographics, disease history, baseline disease assessments, baseline safety assessments, and pregnancy studies. Pretreatment (baseline) samples for PDn and retrospective genomic evaluation will be collected.

[0245] Conduct a safety assessment: - Sequential adverse event (AE) assessment and review of concomitant treatments, Vital signs weekly pre-dose and 2-3 hours post-dose during Cycle 1 and on Day 1 of each subsequent cycle, and at SFU - Clinical biochemistry weekly during cycles 1 and 2, and every other week from cycle 3, then monthly from cycle 7 onwards, and at SFU; - Hematological tests weekly during cycles 1-3, then every other week during subsequent cycles, and at SFU; Troponin at SFU, urine test on day 1 of each cycle and at SFU, - Echocardiogram on Day 1 and SFU of Cycle 2, - Electrocardiogram (ECG) (local reading) on ​​Day 1 of Cycles 1, 2, and each 3rd subsequent cycle, and SFU; - Central ECG on Days 1 and 19 of Cycle 1 (at multiple time points post-dose), and - Physical examination as clinically indicated and dependent on symptoms.

[0246] In addition, intensive blood pressure monitoring, including orthostatic vital signs, will be performed following the first dose of SRA141 on Day 1 of Cycle 1.

[0247] Efficacy is evaluated: Tumor assessment by CT / MRI of the chest, abdomen, pelvis, and all sites of suspected disease after Day 1 of Cycle 1 and every 8 weeks at SFU (except for subjects discontinued due to documented disease progression), - Clinical evaluation and serum carcinoembryonic antigen (CEA) levels after Day 1 of Cycle 1 and every 4 weeks at SFU, and - Survival status

[0248] Evaluating Drug Chemotherapies: - Intensive 24-hour PK sampling on Days 1 and 19 of Cycle 1. - Pre-dose sampling on day 1 of C3, 4, 5, and 8

[0249] Pharmacokinetics will be evaluated. Surrogate tissues (skin punch biopsies) and tumor tissues will be collected and analyzed for the PDn biomarker pMCM2. Skin punch samples will be collected on days 18 or 19 of cycle 1 at baseline and 4-8 hours post-dose (i.e., expected Cmax of SRA141). In some cases, a third skin punch biopsy at a later time point in cycle 1 or a subsequent cycle when the plasma concentration of SRA141 reaches trough levels (Cmin) will be collected from subjects in whom a measurable biomarker effect above SRA141 dose levels is observed from 4-8 hours post-dose on days 18 or 19. The timing of the third skin punch biopsy will be communicated by the sponsor based on emerging PK and PDn data. Skin biopsy samples will be required from all subjects enrolled in the escalation dose phase and from at least 10 subjects in the expansion dose phase. Tumor tissue will be required from at least 6 subjects in the expansion dose phase at baseline and on days 4 or 5 of cycle 1, 4-8 hours post-dose. Tumor tissue from additional subjects in the expansion dose stage and from subjects in the escalation dose stage are optional.

[0250] Genomics will be evaluated. Archival or fresh tumor tissue (primary or metastatic) as well as blood samples will be collected for retrospective genomic analysis at baseline to explore genomic alterations associated with SRA141 treatment response. Blood samples will also be collected at the SFU.

[0251] Inclusion criteria Subjects for clinical trials are selected based on the following criteria: - Written informed consent prior to any trial-specific procedures, sampling, and analyses -Are 18 years of age or older at the time of providing consent Histologically and / or cytologically confirmed metastatic CRC Prior treatment with regimens containing fluorouracil or capecitabine, oxaliplatin, and irinotecan - At least 12 weeks of life Hematological and biochemical indices within the ranges shown in Table 4, measured within 1 week prior to the subject receiving their first dose of IMP [Table 5] - World Health Organization (WHO) performance status 0-1 Radiographically measurable disease according to RECIST criteria - Archaic tumor tissue collected within 18 months prior to the first dose of IMP or approved by the sponsor and available for retrospective tumor profiling or accessible tumor, as well as willingness to consent to biopsy for collection of tumor tissue - For a minimum of 6 subjects enrolled in the expansion phase, accessible tumor and willingness to consent to up to 2 tumor biopsies for collection of tumor tissue for PDn assay

[0252] Exclusion criteria Subjects will be excluded from the clinical trial based on the following criteria: Any prior treatment with a CdC7 inhibitor - Colon cancer with known microsatellite instability high, i.e. MSI-H - Receiving any of the following previous or current anticancer therapies: Radiotherapy of any target lesion (lesion used as measurable disease) within 4 weeks of the first dose of SRA141 (except for symptomatic controls and lesions not used as measurable disease) b. Chemotherapy within 3 weeks of the first dose of SRA141 c. Prior immunotherapy within 4 weeks, or 5 half-lives if shorter and approved by the sponsor, prior to the first dose of SRA141 d. Nitrosoureas or mitomycin C within 6 weeks prior to the first dose of SRA141 e. Any other IMP or targeted therapy within 4 weeks, or 5 half-lives if shorter and approved by the sponsor, prior to the first dose of SRA141 - Current administration of naturopathic drugs, herbal supplements, or other alternative therapies that, in the investigator's opinion, are known to affect CYP450 enzymes - Current non-prescription drug or alcohol dependence that is severe enough in the investigator's opinion to affect study compliance or safety - Other malignancies within the past 2 years, except adequately treated tumors associated with an expected 5-year disease-free survival rate of approximately 95% or greater, unless approved by the sponsor - Ongoing toxic symptoms of prior therapy greater than NCI-CTCAE Grade 1. Exceptions to this are alopecia or specific toxicities that, in the opinion of the investigator and the sponsor or the sponsor's designated monitor, should not exclude the subject -New or ongoing brain metastases. History of central nervous system metastases within the past 6 months (expansion cohort only). Subjects with brain metastases that are radiologically stable for 8 weeks in some cases will be included in the expansion cohort. - Pregnant or lactating women. Women of childbearing potential (WOCBP) are excluded from the study unless they have a negative serum or urine pregnancy test screen (i.e., within 7 days of the first dose) and agree to adhere to effective contraception requirements throughout the study and for 6 months thereafter, beginning with the first dose of IMP. - Able to father a child, unless the partner of childbearing potential agrees to take steps not to father a child by following contraceptive requirements during the study and for 6 months thereafter. Subjects with pregnant or breastfeeding partners must be encouraged to use condoms and spermicidal gel to prevent exposure to the fetus or newborn during the study and for 6 months after the final dose of SRA141 - The subject has not yet recovered from a major operation - High medical risk due to non-malignant systemic disease (including active uncontrolled infection) - Controlled with a negative viral load and known to be serologically positive for Hepatitis B, Hepatitis C, or Human Immunodeficiency Virus (HIV) unless approved by the sponsor - Unless approved by the sponsor, concurrent serious cardiac or cardiovascular conditions such as congestive heart failure, history of class III / IV cardiac disease according to New York Heart Association [NYHA] criteria, left ventricular ejection fraction <45% at baseline, history of cardiac ischemia within the past 6 months, history of significant cardiac arrhythmias requiring treatment, history of ischemic cerebrovascular disease or symptomatic peripheral vascular disease QTcF >450 ms in adults and >470 ms in adult women Prior bone marrow transplant or extensive radiation therapy to >25% of the bone marrow within 8 weeks of the first dose of IMP - Disturbances in gastrointestinal (GI) function or GI disease that in some cases significantly alter the absorption of IMP (e.g., ulcer disease, uncontrolled nausea, vomiting, diarrhea, or malabsorption syndromes) Inability to swallow capsules without chewing or crushing Known allergy, hypersensitivity, or intolerance to SRA141 or any of its excipients - Currently a participant in this clinical trial or planning to participate in another interventional clinical trial. Participation in an observational or interventional clinical trial that does not involve administration of IMP and does not impose an unacceptable burden on the subject in the opinion of the investigator and sponsor or sponsor's designee is acceptable. - Any other condition that in the opinion of the investigator or sponsor makes the subject a good candidate for a clinical trial.

[0253] RECIST criteria The evaluation of disease response in this study is performed according to the revised RECIST criteria v1.1. The RECIST criteria are described in more detail in Eisenhauer, et al. (New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer [Internet]. 2009), which is incorporated herein by reference for all that it teaches.

[0254] At baseline, tumor lesions / lymph nodes are generally classified as measurable or nonmeasurable as follows:

[0255] measurable Tumor Lesions: Generally accurately measured in at least one dimension (the longest diameter in the plane of measurement is recorded) and have a minimum size of: - 10 mm by CT scan (CT scan slice thickness ≤ 5 mm, see Appendix II in Eisenhauer, et al., [Eisenhauer, 2009] for imaging guidance) - 10 mm caliper measurement by clinical examination (lesions that cannot be accurately measured with a caliper should be recorded as non-measurable) - Chest X-ray 20mm

[0256] Malignant lymph nodes: To be considered pathologically enlarged and measurable, lymph nodes generally have a short axis of 15 mm when assessed by CT scan (CT scan slice thickness of 5 mm or less is recommended). At baseline and follow-up, only the short axis is generally measured and tracked.

[0257] unmeasurable All other lesions, including small lesions (pathologic lymph nodes with a longest diameter less than 10 mm or a short axis greater than or equal to 10-15 mm) and truly nonmeasurable lesions. Lesions considered truly nonmeasurable generally include leptomeningeal disease, ascites, pleural or pericardial effusions, inflammatory breast disease, lymphatic lesions of the skin or lung, abdominal masses / organomegaly identified by physical exam that are not measurable by reproducible imaging techniques.

[0258] Bone lesions, cystic lesions, and lesions previously treated with local therapies require specific comments:

[0259] Bone lesions: -Bone scans, PET scans, or plain films are generally not considered adequate imaging techniques for measuring bone lesions. However, these techniques can be used to confirm the presence or absence of bone lesions. -Lytic bone lesions or mixed lytic-blastic lesions with an identifiable soft-tissue component that can be assessed by cross-sectional imaging techniques such as CT or MRI are generally considered measurable lesions if the soft-tissue component meets the definition of measurability above. -Blastoid bone lesions are generally not measurable.

[0260] Cystic lesions: -Lesions that meet the criteria for radiographically defined simple cysts are generally not considered malignant lesions (neither measurable nor nonmeasurable) because, by definition, they are simple cysts. - "Cystic lesions" believed to represent cystic metastases are generally considered to be measurable lesions if they meet the definition of measurability above. However, when non-cystic lesions are present in the same subject, these are preferred for selection as target lesions.

[0261] Previously Locally Treated Lesions: -Tumor lesions in areas that have previously been irradiated or that have received other locoregional therapy are not generally considered measurable unless the lesion has demonstrated progression. Study protocols will generally detail the conditions under which such lesions are generally considered measurable.

[0262] Evaluation method All measurements are recorded, typically in metric notation, using calipers when clinically assessed. All baseline assessments are performed as close as possible to the start of treatment, typically within 4 weeks prior to the start of treatment.

[0263] The same assessment methods and the same techniques are generally used to characterize each lesion identified and reported at baseline and during follow-up. Although the lesion(s) being followed can be imaged, assessment is generally always based on imaging rather than clinical examination, unless assessable by clinical examination.

[0264] Clinical lesions are generally considered measurable if they are superficial and 10 mm or greater in diameter (e.g., skin nodules) as assessed using calipers. For cases of skin lesions, documentation by color photography, including a ruler to estimate the size of the lesion, is suggested. As noted above, when lesions can be assessed by both clinical examination and imaging, imaging assessment is generally performed because it is more objective and, in some cases, is reviewed at the end of the study.

[0265] Chest CT is generally preferred over chest x-ray, especially when progression is the key endpoint, because CT is more sensitive than x-ray, particularly in identifying new lesions. However, in some cases, lesions on chest x-ray are considered measurable if they are well defined and surrounded by aerated lung.

[0266] CT is generally the best reproducible method currently available for measuring lesions selected for response assessment. The guidelines define measurability of lesions on CT scans based on the assumption that the CT slice thickness is 5 mm or less. If the CT scan has a slice thickness greater than 5 mm, the minimum size for a measurable lesion is twice the slice thickness. MRI is also acceptable in certain circumstances (e.g., for body scans). Details regarding the use of both CT and MRI for objective tumor response assessment are provided in publications from Eisenhauer et al.

[0267] Ultrasound is generally not useful in assessing lesion size and is generally not used as a method of measurement. Ultrasound examinations cannot be reproduced in their entirety for later independent review and are operator dependent, so generally it is not possible to guarantee that the same technique and measurements will be taken from one evaluation to the next (described in more detail in Eisenhauer, et al. (2009)). If new lesions are identified by ultrasound over the course of the study, confirmation by CT or MRI is generally recommended. MRI is used instead of CT in some selected cases if there are concerns about radiation exposure with CT.

[0268] The use of endoscopic and laparoscopic techniques for objective tumor assessment is generally not recommended, however, they are generally useful to confirm complete pathologic response when biopsies are obtained or to determine recurrence in studies where complete response or recurrence after surgical resection is the endpoint.

[0269] Tumor markers alone are generally not used to assess objective tumor response. However, if the markers are initially above the upper limit of normal, they are generally normalized for subjects to be considered in complete response.

[0270] Cytology and histology are commonly used to distinguish between PR and CR in the rare cases required by protocol (e.g., residual disease in tumor types such as germ cell tumors where known residual benign tumor may remain). Where effusion is known to be a potential adverse effect of treatment (e.g., with certain taxane compounds or angiogenesis inhibitors), cytological confirmation of the neoplastic origin of any effusion that appears or worsens during treatment is generally considered if measurable tumor meets criteria for response or stable disease to distinguish response (or stable disease) from progressive disease.

[0271] Tumor response assessment To assess objective response or future progression, the overall tumor burden at baseline is generally estimated and used as a comparator for subsequent measurements. Measurable disease is generally defined by the presence of at least one measurable lesion.

[0272] If multiple measurable lesions are present at baseline, all lesions, up to a total of up to five lesions (and up to two lesions per organ) representative of all involved organs, are generally identified as target lesions and recorded and measured at baseline (this means that if a subject has only one or two involved organ sites, up to two and four lesions are recorded, respectively). Target lesions are generally selected based on their size (lesions with the longest diameter), generally representative of all involved organs, plus generally suitable for reproducible repeated measurements. In some cases, the largest lesion is not suitable for reproducible measurement, in a situation where the next largest lesion that can be reproducibly measured is generally selected, as exemplified in Eisenhauer, et al. (2009) in Figure 3.

[0273] Lymph nodes deserve special mention because they are normal anatomical structures and in some cases can be seen by imaging even when not involved by tumor. Pathological nodes defined as measurable and in some cases identified as target lesions generally meet the criteria of a short axis of 15 mm or greater by CT scan. Only the short axis of these nodes generally contributes to the baseline total. The short axis of a node is generally the diameter that is typically used by radiologists to determine if a node is involved by a solid tumor. Node size is usually reported as two dimensions in the plane in which the image is acquired (for CT scans, this is almost always the axial plane; for MRI, in some cases the plane of acquisition is the axial, sagittal, or coronal plane). The smaller of these dimensions is the short axis. For example, an abdominal node reported as 20 mm x 30 mm has a short axis of 20 mm and qualifies as a malignant measurable node. In this example, 20 mm is recorded as the node measurement. All other pathologic nodules (those ≥10 mm but with a short axis <15 mm) are generally considered nontarget lesions. Nodules with a short axis <10 mm are generally considered nonpathologic and are generally not recorded or followed.

[0274] The sum of the diameters for all target lesions (longest for non-nodal lesions, short axis for nodal lesions) is generally calculated and reported as the baseline sum diameter. When lymph nodes are included in the sum, only the short axis is added to the sum, as described above. The baseline sum diameter is generally used as a reference to further characterize any objective tumor regression in the measurable dimensions of disease.

[0275] All other lesions (or sites of disease), including pathological lymph nodes, are generally identified as non-target lesions and are generally recorded at baseline. Measurements are generally not required, and these lesions are generally tracked as "present," "absent," or in rare cases, "definite progression" (more information below). In addition, multiple non-target lesions involving the same organ can be recorded as a single item on the case record form (e.g., "multiple pelvic lymph node enlargement" or "multiple liver metastases").

[0276] Response criteria Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (target or non-target) are reduced to <10 mm in short axis.

[0277] Partial response (PR): At least a 30% reduction in the sum of the diameters of the target lesions, taken as reference for the baseline sum diameter.

[0278] Progressive Disease (PD): At least a 20% increase in the sum of the diameters of the target lesions, taken as reference to the smallest sum (which includes the baseline sum, if this is the smallest on the study). In addition to the 20% relative increase, the sum will generally demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also generally considered progression).

[0279] Stable Disease (SD): Neither shrinking enough to qualify for PR nor increasing enough to qualify for PD, using the minimum summated diameter as a reference.

[0280] Lymph nodes identified as target lesions generally have their actual short axis measurement recorded (measured in the same anatomical plane as the baseline examination), even if the node has generally regressed to less than 10 mm. This means that if lymph nodes are included as target lesions, in some cases the "sum" of the lesions will not be zero, even if the complete response criteria are met, since normal lymph nodes are generally defined as having a short axis of <10 mm. Thus, case report forms or other data collection methods are designed in some cases to have target nodal lesions recorded in a separate section, with each node generally achieving a short axis of <10 mm, in order to qualify for CR. For PR, SD, and PD, the actual short axis measurement of the node is preferably included in the sum of the target lesions.

[0281] During the study, all lesions (nodal and non-nodal) recorded at baseline generally have their actual measurements recorded at each subsequent assessment, even if they are very small (e.g., 2 mm). However, occasionally lesions or lymph nodes recorded as target lesions at baseline become very faint on the CT scan, and in some cases the radiologist feels uncomfortable assigning precise dimensions and in some cases reports them as "too small to measure". When this occurs, it is generally important that the value is recorded in the case report form. If it is the radiologist's opinion that the lesion has likely disappeared, the measurement is generally recorded as 0 mm. If the lesion is thought to be present and is faintly seen, but is too small to measure, a default value of 5 mm is generally assigned. (Note: In general, this rule is unlikely to be used for lymph nodes, since lymph nodes usually have a definable size when normal and are often surrounded by fat, such as the retroperitoneum, but if lymph nodes are thought to be present and are faintly seen, but are too small to measure, a default value of 5 mm is generally assigned in this situation as well). This default value is derived from a CT slice thickness of 5 mm (but does not generally change with varying CT slice thickness). Measurements of these lesions are potentially irreproducible, and therefore providing this default value prevents false responses or progressions based on measurement error. However, again, if the radiologist is able to provide the actual dimension, it is generally recorded, even if it is less than 5 mm.

[0282] When non-nodular lesions "fragment," the longest diameters of the fragmented portions are generally added together to calculate the total target lesion. Similarly, when lesions coalesce, a plane between them is generally maintained, helping to obtain the maximum diameter measurement of each individual lesion. If lesions truly coalesce and cannot be separated, the vector of the longest diameters in this case is generally the maximum longest diameter for the "combined lesion."

[0283] Some non-target lesions, although in some cases actually measurable, are generally not measured, and instead are generally only qualitatively evaluated at time points specified in the protocol.

[0284] Complete Response (CR): Disappearance of all non-target lesions and normalization of tumor marker levels. All lymph nodes were non-pathological in size (<10 mm short axis).

[0285] Non-CR / Non-PD: persistence of one or more non-target lesion(s) and / or maintenance of tumor marker levels above normal limits.

[0286] Progressive Disease (PD): Definite progression of existing non-target lesions (see comments below). (Note: the appearance of one or more new lesions is also considered progression.)

[0287] If a subject has measurable disease, to achieve "clear progression" based on non-target disease, there is generally an overall level of substantial worsening in the non-target disease, and the overall tumor burden has increased sufficiently to merit cessation of therapy, even in the presence of SD or PR in the target disease. A modest "increase" in the size of one or more non-target lesions is usually insufficient to qualify for an apparent progression status. A designation of overall progression based solely on changes in non-target disease despite SD or PR of the target disease is therefore generally extremely rare.

[0288] Subjects with only non-measurable disease occur in some Phase III trials when having measurable disease is not a criterion for study entry. The same general concept as above applies here, but in this example there is no assessment of measurable disease to factor into the interpretation of an increase in non-measurable disease burden. Since worsening of non-target disease is generally not easily quantified (by definition: when all lesions are truly non-measurable), a useful test that can generally be applied when evaluating subjects for overt progression is to consider whether the magnitude of increase in overall disease burden based on changes in non-measurable disease corresponds to the increase that would be required to declare PD for measurable disease, i.e., an increase in tumor burden that represents an additional 73% increase in "volume" (which is equivalent to a 20% increase in diameter in measurable lesions). Examples include an increase in pleural effusion from "trace" to "massive," an increase in lymphangitic disease from focal to widespread, or in some cases, described in the protocol as "sufficient to require a change in therapy." If "overt progression" is seen, the subject is generally considered to have overall PD at that point. While it would be ideal to have objective criteria to apply to non-measurable disease, the nature of the disease generally makes this very difficult, and therefore increases are generally substantial.

[0289] The appearance of new malignant lesions generally indicates disease progression, and therefore some comments regarding the detection of new lesions are generally important. In general, there are no specific criteria for the identification of new radiographic lesions, but the discovery of new lesions is generally obvious, i.e., generally not due to differences in scanning technique, changes in imaging modalities, or findings that are thought to represent something other than tumor (e.g., in some cases, some "new" bone lesions are simply healing or recurrence of existing lesions). This is particularly important when the subject's baseline lesions show partial or complete response. For example, necrosis of liver lesions is frequently reported as a "new" cystic lesion on CT scan reports, but generally is not.

[0290] Lesions identified on follow-up examination in an anatomical location not scanned at baseline are generally considered new lesions and generally indicate disease progression. An example of this would be a subject with visceral disease at baseline who has a brain CT or MRI ordered during the study, which reveals metastases. A subject's brain metastases are generally considered evidence of PD, even if baseline brain imaging was not performed.

[0291] If a new lesion is not evident, for example because of its small size, continued therapy and follow-up evaluations will generally clarify whether it truly represents new disease. If a repeat scan definitely confirms that there is a new lesion, progression is generally declared using the date of the initial scan.

[0292] Although FDG-PET response assessment requires additional testing, it may be reasonable to incorporate the use of FDG-PET scanning to complement CT scanning in the evaluation of progression, especially for potential "new" disease. New lesions based on FDG-PET imaging are generally identified according to the following algorithm: a. Negative FDG-PET at baseline, positive*FDG-PET at follow-up is generally indicative of PD based on new lesions. *A "positive" FDG-PET scan lesion generally means one that is FDG avid with uptake greater than twice that of surrounding tissue on attenuation-corrected images. b. No FDG-PET at baseline and positive FDG-PET at follow-up: - If a positive FDG-PET on follow-up corresponds to a new site of disease confirmed by CT, this is generally PD. -If a follow-up positive FDG-PET is not confirmed by CT as a site of new disease, an additional follow-up CT scan is typically performed to determine if true progression has occurred at that site (if so, the date of PD becomes the date of the initial abnormal FDG-PET scan). A "positive" FDG-PET scan lesion generally means one that is FDG avid with uptake greater than twice that of the surrounding tissue on attenuation-corrected images. - If a positive FDG-PET on follow-up corresponds to a site of pre-existing disease on CT that is not enhancing based on anatomical imaging, this is generally not PD.

[0293] Best overall response assessment The best overall response is generally the best response recorded from the start of study treatment to the end of treatment. If a response is not documented in the study until after the end of therapy, post-treatment evaluations are generally considered in determining the best overall response, unless an alternative anticancer therapy has been administered. The assignment of a subject's best overall response generally depends on the findings of both target and non-target disease, and generally also takes into account the appearance of new lesions.

[0294] In general, it is expected that response assessments will be performed at each protocol-specified time point. Table 5 provides a summary of overall response status calculations at each time point for subjects with measurable disease at baseline.

[0295] When a subject has only non-measurable (and therefore non-target) disease, Table 6 is generally used.

[0296] If no imaging / measurements are performed at all at a particular time point, the subject is generally not evaluable (NE) at that time point. If only a subset of lesion measurements are performed at the time of evaluation, the case is usually also generally considered NE at that time point, unless a compelling argument can be made that the contribution of the individual missing lesion(s) does not change the response at the assigned time point. This would most likely occur in the case of PD. For example, if a subject had a baseline sum of 50mm with three measured lesions, and at follow-up only two lesions were evaluated, but they contributed a sum of 80mm, the subject would generally have achieved PD status, regardless of the contribution of the missing lesions.

[0297] A best overall response is generally determined once all data for a subject is known.

[0298] Best response determination in studies where confirmation of complete or partial response is not generally required: Best response in these studies is generally defined as the best response across all time points (e.g., a subject with SD at first assessment, PR at second assessment, and PD at last assessment has a best overall response of PR). When SD is considered to be the best response, this generally also meets the protocol-specified minimum time from baseline. If the minimum time is not met when SD is otherwise the best time response, the subject's best response generally depends on subsequent assessments. For example, a subject with SD at first assessment and PD at second assessment who does not meet the minimum time for SD will have a best response of PD. The same subject who does not receive follow-up after the first SD assessment is generally considered non-evaluable.

[0299] Nodal disease is included in the target lesion totals, and if the nodules are reduced to a "normal" size (<10 mm), in some cases they still have the measurement reported on the scan. In order not to overestimate progression based on an increase in the size of the nodules, this measurement is generally recorded even if the nodules are normal. As mentioned earlier, this means that in some cases a subject with a CR will not have a total of "zero" on the case report form (CRF).

[0300] Subjects with an overall deterioration in health status necessitating discontinuation of treatment without objective evidence of disease progression at that time are generally reported as "symptomatic worsening." Every effort is generally made to document objective worsening even after cessation of treatment. Symptomatic worsening is generally not a descriptor of objective response, it is a reason for stopping study therapy. The objective response status of such subjects is generally determined by evaluation of target and non-target disease, as shown in Tables 5-6.

[0301] The conditions that define "EP, early death and non-evaluable" are study specific and generally clearly described in each protocol (depending on treatment duration, treatment periodicity).

[0302] In some situations, it is difficult to distinguish between residual disease and normal tissue. When assessment of complete response depends on this decision, it is generally recommended to investigate the residual disease (fine needle aspiration / biopsy) before assigning complete response status. In some cases, FDG-PET is used to upgrade the response to CR in a manner similar to biopsy in cases where residual radiographic abnormalities are thought to represent fibrosis or scarring.

[0303] For unclear findings of progression (e.g., very small and uncertain new lesions, cystic changes, or necrosis of existing lesions), in some cases, treatment is continued until the next scheduled evaluation. If progression is confirmed at the next scheduled evaluation, the date of progression is generally the earlier date of suspected progression. [Table 6] [Table 7]

[0304] Duration of response Duration of overall response is generally measured from the time the CR / PR criterion is first met (whichever is first documented) to the first date recurrent or progressive disease is documented on the study.

[0305] The duration of overall complete response is generally measured from the time a CR criterion is first met to the first date of objective documentation of recurrent disease.

[0306] Stable disease is generally measured from the start of treatment (in randomized trials, from the date of randomization) until progression criteria are met, using the minimum trial sum as reference (if the baseline sum is the smallest, this is the reference for calculating PD).

[0307] Example 23: SRA141 CIN Cancer Clinical Trial To confirm the efficacy of SRA141 monotherapy in treating patients with cancers that have a high rate of chromosomal instability, a clinical trial will be conducted as described in Example 22.

[0308] Example 24: Alternative SRA141 Dosing Regimens Alternative schedules will be explored once sufficient clinical safety and tolerability, PK and activity biomarker data are available. In some cases, alternative dosing schedules will be considered at any time during the trial following discussion between the sponsor and the investigator. In some cases, the need for an alternative schedule is indicated by new safety and tolerability data, PK and / or PDn data. In some cases, alternative schedules include, but are not limited to, the following examples: 7 days on / 7 days off, 14 days on / 14 days off, twice daily dosing, or other variations. Alternative dosing schedule cohorts will be initiated in parallel with or in place of the continuous schedule cohorts in some cases.

[0309] The initial starting dose of the alternative dosing schedule will depend on safety, tolerability, and PK results from the previous cohort. If an alternative schedule is tested after the MTD has been identified with a previous schedule, the starting total weekly dose of the new schedule will not exceed the total weekly dose at the MTD of the previous schedule. If an MTD has not been identified with the previous schedule, dose escalation steps will occur in some cases, but dose escalation will generally not exceed 50% based on total weekly dose.

[0310] Example 25: Immunohistochemical evaluation of SRA141 therapy in a rat MV-4-11 xenograft model of biphenotypic B myelomonocytic leukemia Rats bearing subcutaneous biphenotypic B myelomonocytic leukemia MV-4-11 tumors were treated with 75 mg / kg SRA141 or vehicle BID, or with 100 mg / kg SRA141 QD for 5 days. Tumors were harvested from animals 12 hours after administration of the last dose. Formalin-fixed paraffin-embedded tumors and / or skin were assessed by immunohistochemistry for total MCM2, phosphorylated MCM2 at serine 40 (pMCM2-S40) and serine 53 (pMCM2-S53), phosphorylated MCM2 at serine 41 (pMCM2-S41), and phosphorylated histone H2A.X at serine 139 at steady state.

[0311] As shown in Figure 24A and Figure 24B, the substantial reduction of pMCM2 at S40 and S53 in tumors correlated with changes in skin tissue, suggesting that skin biopsies may be utilized to demonstrate the on-target activity of SRA141. As expected, no effect of pMCM2-S41 was seen after SRA141 treatment, since S41, but not Cdc7, is phosphorylated by Cdks. Thus, the data further demonstrate that SRA141 has specificity for Cdc7 inhibition. Tumors were also analyzed by immunohistochemistry for pHH3, a marker of mitotic cells, or by staining with hematoxylin and eosin (H&E). The results shown in Figure 24C demonstrate that after 5 days of administration, tumors treated with SRA141 resulted in fewer mitotic cells and an increased presence of apoptotic cells compared to vehicle, suggesting the presence of antitumor activity in MV-4-11 tumors treated with SRA141.

[0312] Xenograft tumor evaluation Tumor cells in xenograft tumors (but not in the stroma or surrounding rat tissue) were scored. Scoring was performed semiquantitatively using principal components, with tumor cells scored for total MCM2, pMCM2-S53, pMCM2-S40, and gH2AX reactivity as percentages in differential intensity and H-score. Percentage and intensity measurements are estimated by the scientist in the same relative area of ​​tumor within each xenograft sample (one 40x field from the bottom).

[0313] The H-score approach used to evaluate xenograft tissues involves recording the percentage of tumor cells with nuclear staining on a four-point semiquantitative scale (0, 1+, 2+, 3+) with corresponding differential intensity, where 0 = zero, negative or nonspecific staining, 1+ = low or weak staining, 2+ = moderate or moderate staining, and 3+ = high or strong staining.

[0314] The H-score is calculated by summing the percentage of cells with expression intensity (brown staining) multiplied by their corresponding differential intensity on a four-point semi-quantitative scale (0, 1+, 2+, 3+). Thus, the score ranges from 0 to 300.

[0315] H score = [(%at<1) x 0] + [(%at1+) x 1] + [(%at2+) x 2] + [(%at3+) x 3]

[0316] Evaluation of rat skin Epithelial cells of the epidermis in rat skin samples were co-scored by two scientists. Quantitative scoring was performed using principal components to score epidermal cells for total MCM2, pMCM2-S53, pMCM2-S40, and gH2AX reactivity as a count of positive cells. For each skin sample, four evenly distributed areas were marked for screening. Areas were aligned to the same approximate location in each skin sample. For pMCM2-S53 and pMCM2-S40, the number of positive cells in a 10x field in four representative areas was counted. For gH2AX, the number of positive cells in a 20x field in four representative areas was counted. Cells were counted if staining was easily observed at 10x or 20x, regardless of intensity. To consistently capture the same total area, cells were counted only in the flat epidermis and not in invaginated areas.

[0317] The number of positive skin cells counted over the area analyzed for each skin sample was averaged for each biomarker.The average number of positive skin cells for pMCM2-S53 and pMCM2-S40 was then expressed as a percentage compared to the average number of positive skin cells for total MCM2.The average number of positive skin cells for gH2AX was multiplied by 2 to account for its evaluation at 20 times vs. 10 times (normalization), and was then also expressed as a percentage of the average for total MCM2.

[0318] Skin cell counts were performed by recording the number of positive cells (at arbitrary intensity) counted by two independent scientists in multiple skin areas (two areas for total MCM2, four areas for pMCM2, and gH2AX) in the same approximate location for each sample. The number of positive cells recorded in each skin area for each biomarker was averaged for each sample. The average cell counts for pMCM2-S53, pMCM2-S40, and gH2AX (normalized for magnification) were compared to the percentage of total MCM2. Cell counts were performed at 20x magnification for gH2AX and 10x magnification for all other markers.

[0319] Average count (pMCM2, gH2AX) = [region 1 pos cells] + [region 2 pos cells] + [region 3 pos cells] + [region 4 pos cells] / 4

[0320] Average count (total MCM2) = [region 1 pos cells] + [region 4 pos cells] / 2

[0321] Percentage of total (pMCM2) = [average count pMCM2] / [average count total MCM2] x 100

[0322] Percentage of total (gH2AX) = [average count gH2AX × 2 (normalized)] / [average count total MCM2] × 100

[0323] The results shown in Figures 25A and 25B demonstrate a dose-dependent reduction of pMCM2-S40 in both tumor and skin in a rat MV-4-11 xenograft model.

[0324] Example 26: Immunohistochemical evaluation of human tumors and skin Formalin-fixed paraffin-embedded human tumor and human normal skin samples were evaluated by immunohistochemistry for total MCM2, pMCM2-S53, pMCM2-S40, and gH2AX.

[0325] Human tumor evaluation Tumor cells (but not the stroma or surrounding non-tumor tissue components) in human metastatic colon cancer samples were scored. H-scores were calculated as previously described (Example 25).

[0326] Human Skin Assessment Epithelial cells of the epidermis in human skin samples were co-scored by two scientists. Quantitative scoring was performed using principal components to score epidermal cells for total MCM2, pMCM2-S53, pMCM2-S40, and gH2AX reactivity as a count of positive cells. For each skin sample, two evenly distributed areas were marked for examination. Areas were aligned in the same approximate location in each skin sample and evaluated at 10x for MCM2 and pMCM2. For gH2AX, the number of positive cells at 20x filed in the two areas was counted. Cells were counted if staining was easily observed at 10x or 20x, regardless of intensity. To consistently capture the same total area, cells were counted only within the flat epidermis and not in invaginated areas.

[0327] The number of positive skin cells counted over the area analyzed for each skin sample was averaged for each biomarker.The average number of positive skin cells for pMCM2-S53 and pMCM2-S40 was then expressed as a percentage compared to the average number of positive skin cells for total MCM2.The average number of positive skin cells for gH2AX was multiplied by 2 to account for its evaluation at 20 times vs. 10 times (normalization), and was then also expressed as a percentage of the average for total MCM2.

[0328] Skin cell counts were performed as described in Example 25.

[0329] Average count (total MCM2, pMCM2, gH2AX) = [region 1 pos cells] + [region 2 pos cells] / 2

[0330] Percentage of total (pMCM2) = [average count pMCM2] / [average count total MCM2] x 100

[0331] Percentage of total (gH2AX) = [average count gH2AX × 2 (normalized)] / [average count total MCM2] × 100

[0332] Immunohistochemical evaluation of normal human tissues demonstrates that baseline levels of pMCM-S40 are measurable and comparable to levels in rat skin samples following treatment with vehicle (Figure 26). Thus, human skin appears to be a reasonable surrogate tissue for evaluating SRA141 on-target pharmacodynamics.

[0333] Example 27: Combination of SRA141 with additional antitumor agents in various cancer cell lines The combinatorial activity of SRA141 with nine targeted antitumor agents was evaluated in solid tumor cell lines (Colo-205, SW620, A375 (V600E melanoma)) and hematological cancer cell lines (KG-1, MOLM-13, MV411). Cell viability was assessed using the CTG and CTBlue assays described previously (Example 3). Assays were performed in 96-well plates using staurosporine as an internal control. Cells were incubated with single agents (Phase I) or combinations of SRA141 with a second agent (Phase II) for 72 hours.

[0334] In Phase I, the 20% inhibitory concentration (IC20) and 50% inhibitory concentration (IC50) were determined for each of the following nine agents in all six cell lines: ABT-199, the ATM kinase inhibitor KU-60019, the Aurora B kinase inhibitor barasertib, the MEK inhibitor trametinib, the PI3K pathway inhibitor copanlisib, the retinoid pathway inhibitors bexarotene and tretinoin, the threonine tyrosine kinase (TTK) inhibitor CFI-402257, and the epidermal growth factor inhibitor erlotinib.

[0335] In Phase II, the assay was repeated at fixed concentrations (IC20 and IC50 for each drug) in the presence of each drug and the combination of SRA141, and the assay was performed over a range of concentrations of SRA141. Combination index (CI) values ​​were calculated using the Bliss Independence model (see, e.g., Foucquier and Guedj, Pharmacol. Res. Perspect. 2015 3(3), which is incorporated herein by reference in its entirety). A CI value less than 1 (CI<1) indicates that the combination effect is greater than the expected additive effect.

[0336] The results of combination treatment in Colo-205 cells (Figure 27A and Figure 27G) demonstrate that SRA141 and barasertib act synergistically, especially in the presence of 0.012 μM barasertib. In contrast, the combination of SRA141 and bexarotene appears to have an antagonistic effect. Trametinib and copanlisib appear to have a slight additive effect with SRA141 in Colo-205 cells.

[0337] The results of combination treatment in SW620 cells (Figure 27B) show that barasertib, trametinib, and copanlisib all have a slight additive effect on SRA141. The results of combination treatment in A375 (Figure 27C) and KG-1 (Figure 27D) cells show that trametinib or copanlisib, but not barasertib, have a slight additive effect with SRA141.

[0338] Combination treatment results in MOLM-13 cells (Figure 27E) demonstrate that ABT-199 and SRA141 act synergistically, especially in the presence of 0.1 μM ABT-199. In addition, barasertib (Figure 27H), trametinib, copanlisib, bexarotene, and tretinoin all demonstrate a slight additive effect with SRA141 in MOLM-13 cells.

[0339] The results of combination treatment in MV411 cells (Figure 27F) show that barasertib, copanlisib, and tretinoin all have a slight additive effect in SRA141.

[0340] Example 28: SRA141 synergizes with the inhibition of anti-apoptotic genes Anti-apoptotic genes BCL-XL, BCL-2, and MCL-1 were inhibited in HCT116 and Hela cells using RNAi knockdown. Cells were seeded at 2000 cells / well in 96-well plates and transfected with RNAi / Lipofectamine RNAimax solution at a final concentration of 10 nM. Transformed cells were treated with SRA141 at a range of doses for 72 hours. Cell viability of treated cells transfected with RNAi against CTRL (non-toxic control RNAi), BCL-2, BCL-XL, or MCL-1 was measured using the CTBlue assay described above (Example 3). The data shown in Figure 28A demonstrates that anti-apoptotic genes inhibited by RNAi synergize with SRA141.

[0341] The anti-apoptotic gene BCL-2 was inhibited in Molm-13 cells by treatment with 0.1 μM ABT-199 as previously described (see Examples 6 and 24). Cells were treated with 0.1 μM ABT-199 and SRA141 for 72 hours at SRA141 concentrations ranging from 0.04 μM to 3.30 μM. BCL-2 inhibition and synergy with SRA141 was demonstrated at the following concentrations of SRA141: 0.12 μM, 0.37 μM, 1.10 μM, and 3.30 μM (FIG. 28B), as indicated by combination index values ​​of less than 1 (see Example 24).

[0342] Example 29: Clinical trial evaluation of Cdc7 inhibitors To further confirm the effectiveness of Cdc7 inhibitor for the treatment of cancer in human patients, clinical trials are carried out.Suitable patients include patients diagnosed with cancer (e.g., breast cancer, colon cancer, lung cancer, blood cancer, such as leukemia, lymphoma, myeloma, acute myeloid leukemia (AML) and chronic myeloid leukemia (CML), melanoma, uterine cancer, thyroid cancer, chronic eosinophilic leukemia, diffuse large B-cell lymphoma (DLBCL), bladder cancer, cervical cancer, colorectal cancer (CRC), gastric cancer, endometrial cancer, hepatocellular carcinoma, non-small cell lung cancer, ovarian cancer, prostate cancer, pancreatic cancer, brain cancer, sarcoma, small cell lung cancer, neuroblastoma and head and neck cancer).Patients are orally administered Cdc7 inhibitor SRA-141.The maximum effective dosage is confirmed starting from the optimal dose converted from the above animal experiment. The determination of human equivalent dosages from animal (i.e., rat and / or mouse) studies is a technique known to those skilled in the art (Nair, A. and Jacob, SJ Basic Clin. Pharm; March 2016 7(2):27-31). The dosage of SRA-141 can be 100-5,000 mg, 100-1,000 mg, 1,000-2,000 mg, 2,000-3,000 mg, 3,000-4,000 mg, 4,000-5,000 mg, 1,500-2,500 mg, 500-1,000 mg, 1,000-1,500 mg, 1,500-2,000 mg, 2,000 mg-2,500 mg, 2,500-3,000 mg, 3,000-3,500 mg, 3,500-4,000 mg, 4,000-4,500 mg, or 4,500-5,000 mg. SRA-141 can be administered once daily, twice daily, three times daily, every other day, weekly, monthly, once daily for 1-7 days followed by 1-28 days off, once daily for 1-28 days followed by 1-28 days off, or once daily for 1-28 days followed by 1-28 days off. Patients are monitored for disease progression.

[0343] Example 30: Clinical trial evaluation of Cdc7 inhibitors in combination with additional antitumor agent(s) To further confirm the effectiveness of mTOR pathway inhibitor, DNA polymerase inhibitor, and receptor tyrosine kinase inhibitor, as well as MAPK pathway inhibitor, retinoid pathway regulator, apoptosis regulator, or Cdc7 inhibitor combined with PARP inhibitor in human patients, clinical trials are carried out.Suitable patients include those diagnosed with cancer (e.g., breast cancer, colon cancer, lung cancer, blood cancer, such as leukemia, lymphoma, myeloma, acute myeloid leukemia (AML) and chronic myeloid leukemia (CML), melanoma, uterine cancer, thyroid cancer, chronic eosinophilic leukemia, diffuse large B-cell lymphoma (DLBCL), bladder cancer, cervical cancer, colorectal cancer (CRC), gastric cancer, endometrial cancer, hepatocellular carcinoma, non-small cell lung cancer, ovarian cancer, prostate cancer, pancreatic cancer, brain cancer, sarcoma, small cell lung cancer, neuroblastoma and head and neck cancer). The patient is orally administered Cdc7 inhibitor SRA-141. The patient is simultaneously administered mTOR pathway inhibitor, DNA polymerase inhibitor, and receptor tyrosine kinase inhibitor, MAPK pathway inhibitor, retinoid pathway regulator, apoptosis regulator, PARP inhibitor, or antifolate metabolite in human patient.The maximum effective dosage to be administered is determined by using techniques known to the ordinary skilled in the art.The patient is monitored for disease progression.

[0344] References ●TECreighton, Proteins: Structures and Molecular Properties(WHFreeman and Company,1993) ●ALLehninger, Biochemistry (Worth Publishers, Inc., current addition) ●Sambrook, et al., Molecular Cloning: A Laboratory Manual (2nd Edition, 1989) ●Methods In Enzymology (S. Colowick and N. Kaplan eds., Academic Press, Inc.) ●Remington’s Pharmaceutical Sciences,18th Edition(Easton,Pennsylvania: Mack Publishing Company,1990) ●Carey and Sundberg Advanced Organic Chemistry 3 rd Ed.(Plenum Press) Vols A and B(1992) ●U.S.Patent No.5,145,684 ●U.S.Pat.No.4,107,288 ●Monga SP,Wadleigh R,Sharma A,et al.Intratumoral therapy of cisplatin / epinephrine injectable gel for palliation in patients with obstructive esophageal cancer.Am.J.Clin.Oncol.2000;23(4):386-392 ●Mary M.Tomayko C.,Patrick Reynolds,1989.Determination of subcutaneous tumor size in athymic(nude) mice.Cancer Chemotherapy and Pharmacology,Volume 24,Issue 3,pp 148-154 ●E Richtig,G Langmann,K Mullner,G Richtig and J Smolle,2004.Calculated tumour volume as a prognostic parameter for survival in choroidal melanomas.Eye(2004) 18,619-623 ●Jensen et al.BMC Medical Imaging 2008.8:16 ●Tomayko et al.Cancer Chemotherapy and Pharmacology September 1989,Volume 24,Issue 3,pp 148-154 ●Faustino-Rocha et al.Lab Anim(NY).2013 Jun;42(6):217-24 ●Bonte D,Lindvall C,Liu H,et al.Cdc7-Dbf4 kinase overexpression in multiple cancers and tumor cell lines is correlated with p53 inactivation.Neoplasia.2008;Sep;10(9):920-31. ●Cadigan KM.Wnt signaling: complexity at the surface.J Cell Sci [Internet].2006;119(3):395-402.Available from: http: / / jcs.biologists.org / cgi / doi / 10.1242 / jcs.02826 ●Cheng AN,Jiang SS,Fan CC,et al.Increased Cdc7 expression is a marker of oral squamous cell carcinoma and overexpression of Cdc7 contributes to the resistance to DNA-damaging agents.Cancer Lett [Internet].2013;337(2):218-25.Available from: http: / / dx.doi.org / 10.1016 / j.canlet.2013.05.008 ●Cremolini C,Schirripa M,Antoniotti C,et al.First-line chemotherapy for mCRC-a review and evidence-based algorithm.Nat Rev Clin Oncol [Internet].2015;12(10):607-19.Available from: http: / / dx.doi.org / 10.1038 / nrclinonc.2015.129 ●Dienstmann R,Vermeulen L,Guinney J,et al.Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer.Nat Rev Cancer [Internet].2017 [cited 2017 Mar 3];17.Available from: http: / / www.nature.com.proxy.lib.umich.edu / nrc / journal / v17 / n2 / pdf / nrc.2016.126.pdf ●Ferlay J,Soerjomataram I,Ervik M,Dikshit R,Eser S,Mathers C,Rebelo M,Parkin DM,Forman D,Bray,F.GLOBOCAN 2012 v1.0,Cancer Incidence and Mortality Worldwide: IARC CancerBase No.11 [Internet].Lyon,France:International Agency for Research on Cancer;2013.Available from:http: / / globocan.iarc.fr,accessed on 14 May 2018. ●Fodde R,Kuipers J,Rosenberg C,et al.Mutations in the APC tumour suppressor gene cause chromosomal instability.Nat Cell Biol [Internet].2001;3(4):433-8.Available from:http: / / eutils.ncbi.nlm.nih.gov / entrez / eutils / elink.fcgi?dbfrom=pubmed&id=11283620&retmode=ref&cmd=prlinks%5Cnpapers2: / / publication / doi / 10.1038 / 35070129 ●Gregory GP,Hogg SJ,Kats LM,et al.CDK9 inhibition by dinaciclib potently suppresses Mcl-1 to induce durable apoptotic responses in aggressive MYC-driven B-cell lymphoma in vivo.Leukemia.2015;29:1437-1441. ●Guinney J,Dienstmann R,Wang X,et al.The consensus molecular subtypes of colorectal cancer.Nat Med [Internet].2016 Oct 12 [cited 2017 Mar 17];21(11):1350-6.Available from:http: / / www.nature.com / doifinder / 10.1038 / nm.3967 ●Hailey JR,Nold JB,Brown RH,et al.Biliary Proliferation Lesions in the Sprague-Dawley Rat Adverse / Non-adverse.Toxicologic Pathology.2013;42(5):844-854 ●Hou Y,Wang H-Q,Ba Y.High expression of cell division cycle 7 protein correlates with poor prognosis in patients with diffuse large B-cell lymphoma.Med Oncol [Internet].2012;29(5):3498-503.Available from:http: / / link.springer.com / 10.1007 / s12032-012-0223-y ●Howlader N,Noone AM,Krapcho M,Miller D,Bishop K,Kosary CL,Yu M,Ruhl J,Tatalovich Z,Mariotto A,Lewis DR,Chen HS,Feuer EJ,Cronin KA(eds).SEER Cancer Statistics Review,1975-2014,National Cancer Institute.Bethesda,MD,http: / / seer.cancer.gov / csr / 1975_2014 / ,based on November 2016 SEER data submission,posted to the SEER web site,April 2017 ●Huggett MT,Tudzarova S,Proctor I,et al.Cdc7 is a potent anti-cancer target in pancreatic cancer due to abrogation of the DNA origin activation checkpoint.Oncotarget [Internet].2016 Apr;7(14):18495-507.Available from:http: / / www.oncotarget.com / abstract / 7611 ●ICH Harmonised Tripartite Guideline:Nonclinical Evaluation For Anticancer Pharmaceuticals S9.International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use.2009. ●Iwai K,Gotou M,Yamanaka K,Ohashi A.Phospho-proteomics analysis to determine the signaling pathways affected by a novel CDC7-selective inhibitor TAK-931.AACR Annual Meeting 2018.Abstract 2312. ●Larasati,& Duncker,B.P.(2016).Mechanisms Governing DDK Regulation of the Initiation of DNA Replication.Genes,8(1),3.https: / / doi.org / 10.3390 / genes8010003 ●Montagnoli A,Tenca P,Sola F,et al.Cdc7 Inhibition Reveals a p53-Dependent Replication Checkpoint That Is Defective in Cancer Cells.Cancer Res.2004;64(19):7110-6. ●Rodriguez-Acebes S,Proctor I,Loddo M,et al.Targeting DNA replication before it starts:Cdc7 as a therapeutic target in p53-mutant breast cancers.Am J Pathol [Internet].2010 Oct;177(4):2034-45.Available from:http: / / www.ncbi.nlm.nih.gov / pubmed / 20724597 ●Schukken KM,Foijer F.CIN and Aneuploidy:Different Concepts,Different Consequences.BioEssays.2018;40(1):1-9. ●Swords R,Mahalingam D,O’Dwyer M,et al.Cdc7 kinase - A new target for drug development.Eur J Cancer [Internet].2010 Jan;46(1):33-40.Available from:http: / / dx.doi.org / 10.1016 / j.ejca.2009.09.020 ●Therkildsen C,Bergmann TK,Henrichsen-Schnack T,Ladelund S,Nilbert M.The predictive value of KRAS,NRAS,BRAF,PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer:A systematic review and meta-analysis.Acta Oncol(Madr).2014;53(7):852-64. ●Xiang SY,Lilly E.A selective CDC7 inhibitor(LY3177833) impacts chromosome dynamics and has robust and durable activity in PDX tumor models.AACR Annual Meeting 2016.Late breaking abstract. ●Zehir A,Benayed R,Shah RH,et al.Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.Nat Med [Internet].2017;23(6).Available from:http: / / www.nature.com / doifinder / 10.1038 / nm.4333

Claims

1. 1. A composition for use in a method of treating cancer, said composition comprising an SRA141 compound of formula (ID): The method includes administering to a subject having cancer a therapeutically effective amount of an SRA141 compound of formula (ID): 【Chemistry 1】 The therapeutically effective amount is an absolute dose of 100 to 400 mg / day. composition.

2. The subject is a patient having a disease profile similar to that described in Table 4: 【Table 1】 or the subject has not previously received Cdc7 inhibitor therapy; A composition for use according to claim 1.

3. the therapeutically effective amount is at least 160 mg / day, or at least 320 mg / day; or the therapeutically effective amount is at least 150 mg / day, at least 200 mg / day, at least 250 mg / day, at least 300 mg / day, or at least 350 mg / day; or the therapeutically effective amount is at least 200 mg / day, or at least 300 mg / day; A composition for use according to claim 1 or 2.

4. the composition is administered orally, and / or the composition is administered daily, optionally, the composition is administered for at least 5 consecutive days, at least 7 consecutive days, or at least 14 consecutive days; and / or the composition is administered according to a dosing schedule selected from the group consisting of 5 days of administration followed by 2 days off each week, 1 week of daily administration followed by 1, 2, or 3 weeks off, 2 or 3 weeks of daily administration followed by 1 or 2 weeks off, and administration on days 2 and 3 of a weekly cycle; A composition for use according to any one of claims 1 to 3.

5. the therapeutically effective amount is administered in a single dose once daily; or One-half of the therapeutically effective amount is administered twice daily. A composition for use according to any one of claims 1 to 4.

6. the cancer is selected from the group consisting of melanoma, uterine cancer, thyroid cancer, blood cancer, bladder cancer, breast cancer, cervical cancer, colorectal cancer (CRC), gastric cancer, endometrial cancer, hepatocellular carcinoma, leukemia, lymphoma, myeloma, non-small cell lung cancer, ovarian cancer, prostate cancer, pancreatic cancer, brain cancer, sarcoma, small cell lung cancer, neuroblastoma, and head and neck cancer; or the cancer is a hematological cancer selected from the group consisting of acute myeloid leukemia (AML), chronic myeloid leukemia (CML), chronic eosinophilic leukemia, and diffuse large B-cell lymphoma (DLBCL); or the cancer is AML, or The cancer is metastatic colorectal cancer (mCRC); A composition for use according to any one of claims 1 to 5.

7. the cancer is not classified as having high microsatellite instability (MSI-H) status, and optionally the MSI-H status is determined by detection of repetitive DNA sequences selected from the group consisting of mononucleotide repeat markers, dinucleotide repeat markers, quasi-monomorphic markers, and combinations thereof; or the cancer is classified as having microsatellite stable (MSS) status; A composition for use according to any one of claims 1 to 6.

8. the cancer-associated tumor comprises a phenotype selected from the group consisting of chromosomal instability (CIN), a main axis checkpoint assembly defect, a mitotic defect, a G1 / S checkpoint defect, and a combination thereof; or the tumor associated with the cancer comprises a Wnt signaling pathway mutation, and optionally the Wnt signaling pathway mutation is selected from the group consisting of an adenomatous polyposis coli (APC) gene mutation, a FAT1 mutation, a FAT4 mutation, and a combination thereof; A composition for use according to any one of claims 1 to 7.

9. 9. The composition for use according to any of claims 1 to 8, wherein the method further comprises screening tumors associated with said cancer using either archival or fresh tumor biopsies, and optionally, said screening comprises examining patterns of chromosomal segregation by histochemical staining, examining pharmacokinetic markers by histochemical staining, or a combination thereof.

10. The method further comprises administering to the subject a plasma C of the SRA141 compound of greater than 600 ng / mL, greater than 1000 ng / mL, or greater than 1400 ng / mL in the subject after administration. max and / or The method further comprises determining in the subject after administration an AUC of the SRA141 compound of greater than 5800 ng-h / mL, greater than 11900 ng-h / mL, or greater than 16400 ng-h / mL. last and / or the method results in an intratumoral concentration of the SRA141 compound in the subject after administration of greater than 500 ng / mL, greater than 600 ng / mL, greater than 900 ng / mL, or greater than 1300 ng / mL. A composition for use according to any one of claims 1 to 9.

11. A composition for use according to any of claims 1 to 10, wherein the method results in in vivo inhibition of MCM2 phosphorylation, optionally wherein the in vivo inhibition of MCM2 phosphorylation is at amino acid residues Ser40 and / or Ser53.

12. The composition for use according to any of claims 1 to 11, wherein said method results in the inhibition of growth of tumors or lesions associated with said cancer.

13. the growth inhibition is determined by comparing a second diameter of a target lesion after administration of SRA141 to a first diameter of the target lesion before administration of SRA141; or The composition for use according to claim 12, wherein the growth inhibition is determined by comparing the sum of the second diameters of the target lesions after administration of SRA141 with the sum of the first diameters of the target lesions before administration of SRA141.

14. the growth of said tumor or lesion is inhibited by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% compared to an untreated tumor; or said growth inhibition of said tumor is at least 47% minimal growth inhibition compared to an untreated tumor; or said growth inhibition of said tumor is at least 93% minimal growth inhibition compared to an untreated tumor; A composition for use according to claim 12 or 13.

15. the method results in regression of a tumor associated with the cancer; or the method results in cytotoxicity of tumors associated with the cancer; or the method results in at least a 30% reduction in the sum of the diameters of tumors associated with the cancer; or the method results in a partial response, a complete response, or stable disease in the subject. A composition for use according to any one of claims 1 to 14.

16. 16. The composition for use according to any of claims 1 to 15, wherein the method further comprises administering to the subject a second therapeutically effective amount of one or more additional therapeutic agents, and wherein the cancer is selected from the group consisting of hematological cancer, leukemia, lymphoma, myeloma.

17. the one or more additional therapeutic agents comprises an anti-tumor agent; the antitumor agent is selected from the group consisting of a DNA polymerase inhibitor, a receptor tyrosine kinase inhibitor, a mammalian target of rapamycin (mTOR) pathway inhibitor, or the antitumor agent comprises a mitogen-activated protein kinase (MAPK) pathway inhibitor; or the anti-tumor agent comprises a retinoid pathway regulator; or the anti-tumor agent comprises an apoptosis regulator; or the antitumor agent comprises a phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway inhibitor; or the antitumor agent comprises a PARP inhibitor; or the antitumor agent comprises an Aurora B kinase inhibitor; 17. A composition for use according to claim 16.

18. the MAPK inhibitor is trametinib; the retinoid pathway regulator is bexarotene, an RXR agonist, or tretinoin (all-trans retinoic acid, ATRA), an RAR agonist; the apoptosis regulator comprises a BCL-2 inhibitor; the BCL-2 inhibitor is ABT-199; the PI3K pathway inhibitor is copanlisib; the PARP inhibitor is BMN673; The Aurora B kinase inhibitor is barasertib.

18. A composition for use according to claim 17.

19. The composition for use according to any of claims 16 to 18, wherein the combination of the SRA141 compound and the one or more additional therapies exhibits a synergistic effect.

Citation Information

Patent Citations

  • Novel furanone derivative

    WO2012133802A1

  • Anticancer agent composition

    WO2015115355A1